bendamustine hydrochloride has been researched along with Leukemia, Lymphocytic, Chronic, B-Cell in 244 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 40 (16.39) | 29.6817 |
| 2010's | 158 (64.75) | 24.3611 |
| 2020's | 46 (18.85) | 2.80 |
| Authors | Studies |
|---|---|
| Babu, S; Boxer, MA; Burke, JM; Danilov, AV; Li, J; Masaquel, AS; Mun, Y; Sharman, JP; Trask, PC; Yimer, HA | 1 |
| Leslie, LA | 1 |
| He, Y; Hu, J; Hu, Y; Jin, J; Lv, Y; Ma, H; Meng, F; Wang, C; Wu, D; Xu, W; Yan, J; Yu, K; Zhang, X; Zhao, C; Zhao, X; Zhao, Y; Zhou, D | 1 |
| Dhande, P; Girkar, N; Pawar, S; Zaki, S | 1 |
| Andriani, A; Autore, F; Cimino, G; Del Poeta, G; Ditto, C; Fresa, A; Innocenti, I; Laurenti, L; Maglione, R; Mauro, FR; Mengarelli, A; Padua, L; Papa, E; Pelliccia, S; Principe, MID; Romeo, A; Stefanizzi, C; Tafuri, A | 1 |
| Aurer, I; Babic, A; Batinic, D; Lalic, H; Smoljo, T; Visnjic, D | 1 |
| Assouline, S; Boyer, M; Cartron, G; Chyla, B; D'Rozario, J; de la Serna, J; Eichhorst, BF; Jaeger, U; Jiang, Y; Kater, AP; Kipps, TJ; Lamanna, N; Lefebure, M; Lu, T; Mellink, C; Montillo, M; Owen, CJ; Panchal, A; Robak, T; Seymour, JF; Wu, JQ | 1 |
| Cuker, A; Dhopeshwarkar, N; Hennessy, S; Leonard, CE; Rhodes, JM; Yang, W | 1 |
| Al-Sawaf, O; Böttcher, S; Cramer, P; Eichhorst, BF; Fink, AM; Fischer, K; Fürstenau, M; Hallek, M; Illmer, T; Klaproth, H; Kreuzer, KA; Langerbeins, P; Ritgen, M; Robrecht, S; Stilgenbauer, S; Tausch, E; von Tresckow, J; Wendtner, CM | 1 |
| Al-Sawaf, O; Böttcher, S; Brüggemann, M; Cramer, P; Dreger, P; Eichhorst, B; Fink, AM; Fischer, K; Fürstenau, M; Giza, A; Hallek, M; Kneba, M; Kreuzer, KA; Langerbeins, P; Ritgen, M; Robrecht, S; Schetelig, J; Schilhabel, A; Schneider, C; Stilgenbauer, S; Tausch, E; Zhang, C | 1 |
| Blachnio, K; Grygalewicz, B; Kawiak, J; Pienkowska-Grela, B; Rygier, J; Rymkiewicz, G; Woroniecka, R | 1 |
| De la Serna-Torroba, J; Escudero-Vilaplana, V; Hernández-Rivas, JÁ; Moreno-Martínez, E; Sánchez-Cuervo, M; Sánchez-Hernández, R | 1 |
| Böttcher, S; Decker, T; Eichhorst, B; Fink, AM; Fischer, K; Hallek, M; Heinisch, K; Holmes, EE; Kreuzer, KA; Kutsch, N; Müller-Hagen, S; Ritgen, M; Robrecht, S; Schüler, G; Stilgenbauer, S; Vehling-Kaiser, U; Wendtner, CM | 1 |
| Aarup, K; Andersen, MA; Enggaard, L; Frederiksen, H; Nielsen, T; Niemann, CU; Poulsen, CB; Rotbain, EC; Vainer, N; Wind-Hansen, L | 1 |
| Fan, L; Jiang, R; Li, JY; Mi, HL; Miao, Y; Qin, SC; Qiu, JY; Sha, YQ; Wang, L; Wu, W; Xu, W; Zhu, HY | 1 |
| Bahlo, J; Baumann, M; Brüggemann, M; Christiansen, I; da Cunha-Bang, C; De Silva, N; Eichhorst, B; Enggaard, L; Fink, AM; Fischer, K; Frederiksen, H; Fürstenau, M; Gaska, T; Geisler, C; Goede, J; Gregor, M; Hallek, M; Hebart, H; Hoogendoorn, M; Illmer, T; Jäger, U; Janssens, A; Juliusson, G; Kater, AP; Koene, H; Kreuzer, KA; Levin, MD; Leys, MBL; Lindström, V; Lotfi, K; Niemann, CU; Nösslinger, T; Poulsen, CB; Regelink, JC; Ritgen, M; Robrecht, S; Schneider, C; Schöttker, B; Simon, F; Staber, PB; Stilgenbauer, S; Tadmor, T; Tausch, E; Thornton, P; van der Klift, M; van Oers, M; von Tresckow, J; Wendtner, CM; Widmer, A; Zhang, C | 1 |
| Baltasar Tello, P; Bravo, J; Champ, D; Delgado, J; Fernández Zarzoso, M; Forés, R; Garcia-Marco, JA; Gironella, M; González Garcia, E; Medina Perez, A; Páyer, AR; Ríos Herranz, E; Terol Castera, MJ | 1 |
| Bartlett, N; Byrd, JC; Ding, W; El-Jawahri, A; Johnson, PC; Lage, DE; Lavoie, MW; Le-Rademacher, J; Mandrekar, SJ; Marcotte, V; Nelson, AM; Newcomb, RA; Nipp, RD; Owen, C; Rice, J; Ritchie, CS; Rosko, A; Ruppert, AS; Stephens, DM; Stone, R; Ulrich, A; Woyach, JA | 1 |
| Afzali, M; Faraji, H; Fariman, S; Momeni Nasab, F | 1 |
| Geiger, AJ; Sitwala, KV; Yasar, DG | 1 |
| Chen, X; Hong, Y; Huang, Z; Mi, J; Wang, Y; Xiao, X; You, X; Zheng, P; Zhou, T | 1 |
| da Cunha-Bang, C; Egholm, GJ; Enggard, L; Frederiksen, H; Hjalgrim, H; Niemann, CU; Poulsen, CB; Rostgaard, K; Rotbain, EC; Zahedi, B | 1 |
| Bramowicz-Jarosz, B; Długosz-Danecka, M; Graboś-Michalak, J; Hus, I; Kopacz, A; Krochmalczyk, D; Malenda, A; Piotrowska, M; Potoczek, S; Raźny, M; Seweryn, M; Soroka-Wojtaszko, M; Szymczyk, A; Wąsik-Szczepanek, E; Wichary, R; Wołowiec, D; Zawirska, D | 1 |
| Al-Sawaf, O; Cramer, P; Döhner, H; Dreyling, M; Eichhorst, B; Fink, AM; Fischer, K; Fürstenau, M; Goede, V; Hallek, M; Hensel, M; Hoechstetter, M; Hopfinger, G; Jaeger, U; Kiehl, MG; Kneba, M; Kutsch, N; Lange, E; Langerbeins, P; Maurer, C; Robrecht, S; Stilgenbauer, S; Theurich, S; Tresckow, JV; von Bergwelt-Baildon, M; Wendtner, CM | 1 |
| Barrientos, JC; Delgado, J; Egyed, M; Eradat, H; Illés, Á; Jurczak, W; Montillo, M; Morschhauser, F; Pristupa, AS; Robak, T; Schuh, A; Shreay, S; Wach, M; Zelenetz, AD | 1 |
| Bachy, E; Baseggio, L; Besson, H; Callet-Bauchu, E; Diels, J; Doubek, M; Garside, J; Healy, N; Hermans, R; Iraqi, W; Lundbom, J; Lysak, D; Panovska, A; Pick-Lauer, C; Salles, G; Simkovic, M; Smolej, L; Spacek, M; Urbanova, R | 1 |
| Al-Sawaf, O; Bahlo, J; Böttcher, S; Cramer, P; Dürig, J; Eichhorst, B; Fink, AM; Fischer, K; Fürstenau, M; Hallek, M; Heinz, WJ; Hensel, M; Kneba, M; Kreuzer, KA; Langerbeins, P; Pflug, N; Ritgen, M; Robrecht, S; Sasse, S; Stilgenbauer, S; Tausch, E; Tresckow, JV; Vehling-Kaiser, U; Wendtner, CM | 1 |
| Gordiienko, I; Ivanivska, T; Shcherbina, V; Shlapatska, L; Sidorenko, S | 1 |
| Bloehdorn, J; Döhner, H; Lichter, P; Mertens, D; Stilgenbauer, S; Yosifov, DY | 1 |
| Brejcha, M; Brychtová, Y; Doubek, M; Koriťáková, E; Lysák, D; Mašlejová, S; Nekvindová, L; Němcová, L; Novák, J; Panovská, A; Papajík, T; Plevová, K; Pospíšilová, Š; Poul, H; Šimkovič, M; Smolej, L; Špaček, M; Starostka, D; Urbanová, R; Vodárek, P; Vrbacký, F; Zuchnická, J | 1 |
| Avery, E; Campbell, P; de la Serna, J; Dolan, S; Ghia, P; Illes, A; Jacob, A; Jurczak, W; Kaplan, P; Kozak, T; Kraychok, I; Lee, JH; Liang, W; Lysak, D; Musuraca, G; Patel, P; Pluta, A; Quah, C; Simkovic, M; Wach, M | 1 |
| Mondello, P; Zelenetz, AD | 1 |
| Avigdor, A; Balasubramanian, S; Bartlett, NL; Chanan-Khan, A; Connor, A; Cramer, P; Demirkan, F; Dilhuydy, MS; Fraser, GAM; Goy, A; Grosicki, S; Hallek, M; Howes, A; Janssens, A; Loscertales, J; Mato, A; Mayer, J; Nottage, K; Pavlovsky, MA; Rule, S; Salman, M; Samoilova, O; Santucci Silva, R; Schuier, N; Sun, S; Tamegnon, M | 1 |
| Asklid, A; Hansson, L; Johansson, H; Lundin, J; Mansouri, L; Mattsson, A; Österborg, A; Rosenquist, R; Sylvan, SE; Wiggh, J; Winqvist, M | 1 |
| Beech, A; Bishton, M; Fox, CP; Gaiolla, R; Hartley, S; Knight, H; Martinez-Calle, N; Smith, D | 1 |
| Allan, JN; Barr, PM; Billio, A; Brander, DM; Cavallari, M; Cimino, G; Coscia, M; Cucci, R; Cuneo, A; de la Serna, J; Di Raimondo, F; Doubek, M; Farina, L; Ferrarini, I; Foà, R; Gaidano, G; Gentile, M; Ghia, P; Hill, BT; Ilariucci, F; Jacobs, R; Lamanna, N; Lansigan, F; Laurenti, L; Marchetti, M; Mato, AR; Mauro, FR; Medina Perez, A; Molica, S; Orlandi, EM; Pagel, JM; Piciocchi, A; Pu, JJ; Rigolin, GM; Roeker, L; Schuster, SJ; Sehgal, AR; Shadman, M; Shah, NN; Skarbnik, AP; Spacek, M; Tam, CS; Tedeschi, A; Trentin, L; Ujjani, CS; Vignetti, M; Winter, A | 1 |
| Cartron, G; Eichhorst, B; Giever, T; Hallek, M; Huang, H; Humphrey, K; Jiang, Y; Kozloff, MF; Lozanski, G; Mobasher, M; Morschhauser, F; Pignataro, DS; Salles, G; Schary, W; Stilgenbauer, S; Wendtner, CM | 1 |
| Cerchione, C; Della Pepa, R; Giordano, C; Leone, A; Pane, F; Picardi, M; Pugliese, N; Vitiello, S | 1 |
| Afik, R; Chodick, G; Cohen, R; Herishanu, Y; Kan, I; Sail, K; Shalev, V; Weil, C | 1 |
| Abraham, I; Bartels, T; Kumar, A; McBride, A; Moore, L; Persky, DO | 1 |
| Choudhry, A; Irwin, D; Thompson, S; Wilson, K | 1 |
| Andersen, MA; da Cunha-Bang, C; Frederiksen, H; Grønbaek, K; Hjalgrim, H; Niemann, CU; Rostgaard, K; Rotbain, EC | 1 |
| Bosch, F; Böttcher, S; Foà, R; Ilhan, O; Kisro, J; Leblond, V; Mahé, B; Mikuskova, E; Osmanov, D; Perretti, T; Reda, G; Robinson, S; Stilgenbauer, S; Tausch, E; Trask, P; Turgut, M; Van Hoef, M; Wójtowicz, M | 1 |
| Rose, GE; Thaung, C; Vahdani, K | 1 |
| Al-Janazreh, H; Angeletti, I; Biagi, A; Bomben, R; Bossio, S; Cassin, R; Chiarenza, A; Condoluci, A; Consoli, U; Coscia, M; Cuneo, A; Cutrona, G; D Arrigo, G; Del Giudice, I; Del Poeta, G; Di Raimondo, F; Ferrarini, M; Foà, R; Fronza, G; Gaidano, G; Galimberti, S; Gattei, V; Gentile, M; Herishanu, Y; Laurenti, L; Loseto, G; Martino, EA; Mauro, FR; Menichini, P; Moia, R; Monti, P; Morabito, F; Murru, R; Neri, A; Olivieri, J; Pietrasanta, D; Polliack, A; Rago, A; Reda, G; Rossi, D; Rossi, FM; Scortechini, I; Sportoletti, P; Trentin, L; Tripepi, G; Varettoni, M; Vigna, E; Visentin, A; Zucchetto, A | 1 |
| Allsup, D; Bloor, A; Emmerson, J; Hillmen, P; Hockaday, A; Howard, D; Munir, T; Nathwani, A; Oughton, JB; Paneesha, S; Phillips, D; Rawstron, A; Turner, D | 1 |
| Al-Sawaf, O; Cramer, P; Eichhorst, B; Fink, AM; Fischer, K; Fürstenau, M; Giza, A; Hallek, M; Kneba, M; Langerbeins, P; Pelzer, BW; Robrecht, S; Schneider, C; Stilgenbauer, S; Tausch, E; von Tresckow, J; Wendtner, CM | 1 |
| Abramson, JS; Bartlett, NL; Booth, AM; Brander, DM; Brown, JR; Byrd, JC; Coutre, S; Ding, W; Erba, H; Kuzma, CS; Larson, RA; Little, RF; Litzow, M; Mandrekar, SJ; Nattam, S; Owen, C; Ruppert, AS; Smith, SE; Stone, RM; Woyach, JA | 1 |
| Abdel-Samad, N; Booth, AM; Chen, BE; Cheung, MC; Couban, S; Crump, M; Fraser, GAM; Hay, AE; Lam, S; Mandrekar, SJ; McDonald, G; Mittmann, N; Owen, C; Prica, A; Ruppert, AS; Shepherd, LE; Sperlich, C; van der Jagt, R; Woyach, JA; Yen, H | 1 |
| Barr, PM; James, L; Kahl, B; Martin, P; Pathak, A | 1 |
| Andrasiak, I; Knopinska-Posluszny, W; Rybka, J; Wrobel, T | 1 |
| Bowen, D; Boysen, J; Call, T; Conte, M; Ding, W; Erlichman, C; Habermann, TM; Hanson, C; Jelinek, D; Kay, NE; LaPlant, B; Larsen, JT; Leis, JF; Lesnick, C; Nikcevich, D; Pettinger, A; Reeder, C; Secreto, C; Shanafelt, TD; Tschumper, R | 1 |
| Anthony, SP; Chanas, B; Cheung, EM; Edenfield, WJ; Hepner, A; Mattar, B; Mutch, PJ; Smith, M | 1 |
| Brown, JR; Danilov, AV; Gordon, MJ; Lewis, LD | 1 |
| Baculea, S; Cote, S; Mealing, S; Singh, M; Whelan, J | 1 |
| Dean, AB; Hernandez-Ilizaliturri, F; Kramer, L; Qiu, J; Snyder-Keller, A; Sui, H; Sun, S; Wu, Y; Yang, Y | 1 |
| Chan, EKH; Chanan-Khan, A; Cramer, P; Diels, J; Dilhuydy, MS; Fraser, G; Goy, A; Grosicki, S; Howes, A; Janssens, A; Loscertales, J; Mahler, M; Rule, S; Salman, M; Santucci-Silva, R; Sengupta, N; Traina, S | 1 |
| Aktan, M; Bernhardt, A; Hiddemann, W; Ilhan, O; Johansson, P; Kellershohn, K; Laribi, K; Leblond, V; Meddeb, B; Messeri, D; Michallet, AS; Moreno, C; Osborne, S; Raposo, J; Schuh, A; Ünal, A; Widenius, T | 1 |
| Bahlo, J; Böttcher, S; Cramer, P; Eichhorst, B; Engelke, A; Fink, AM; Fischer, K; Hallek, M; Kreuzer, KA; Langerbeins, P; Stilgenbauer, S; von Tresckow, J; Wendtner, CM | 1 |
| Assouline, S; Boyer, M; Cartron, G; D'Rozario, J; De la Serna, J; Eichhorst, B; Gerecitano, J; Hillmen, P; Humerickhouse, R; Humphrey, K; Jaeger, U; Kater, AP; Kipps, TJ; Li, Y; Mobasher, M; Montillo, M; Owen, C; Punnoose, EA; Robak, T; Seymour, JF | 1 |
| Wendtner, CM | 1 |
| Angrilli, F; Chaffee, KG; Chiarenza, A; Ciolli, S; Cortelezzi, A; Coscia, M; Cutrona, G; D'Arrigo, G; Del Poeta, G; Del Principe, MI; Di Raimondo, F; Di Renzo, N; Ferrarini, M; Foà, R; Gaidano, G; Gentile, M; Giordano, A; Herishanu, Y; Innocenti, I; Laurenti, L; Mauro, FR; Molica, S; Morabito, F; Neri, A; Parikh, SA; Polliack, A; Recchia, AG; Reda, G; Rossi, D; Shanafelt, TD; Shvidel, L; Tadmor, T; Tripepi, G; Uccello, G; Vigna, E; Zirlik, K | 1 |
| Amendola, A; Billio, A; Bowles, KM; Chiarenza, A; Ciolli, S; Cortelezzi, A; Coscia, M; Cuneo, A; de la Serna, J; Delgado, AR; Eyre, TA; Farina, L; Foà, R; Follows, G; Forconi, F; Gaidano, G; Galieni, P; Ghia, P; Gonzalez, M; Ilariucci, F; Kennedy, B; Laurenti, L; Marasca, R; Marchetti, M; Mauro, FR; Meneghini, V; Molica, S; Montillo, M; Moreno, C; Musuraca, G; Orlandi, EM; Perez, AM; Piciocchi, A; Re, F; Rigolin, GM; Schuh, A; Smolej, L; Tedeschi, A; Trentin, L; Vignetti, M; Visco, C | 1 |
| Bosch, F; Böttcher, S; Foà, R; Gresko, E; Ilhan, O; Knauf, W; Leblond, V; Lundberg, L; Mikuskova, E; Moore, T; Morris, T; Renner, C; Robson, S; Stilgenbauer, S; Tausch, E; Woszczyk, D | 1 |
| Rachshtut, M; Shikdar, S; Totton, D; Turco, T | 1 |
| Brown, JR | 1 |
| Aktan, M; Bosch, F; Dartigeas, C; Ferra Coll, CM; Foà, R; Gresko, E; Kisro, J; Leblond, V; Merot, JL; Montillo, M; Raposo, J; Robson, S; Stilgenbauer, S | 1 |
| Eren, R; Suyanı, E | 1 |
| Armitage, JO; Kallam, A | 1 |
| Al-Sawaf, O; Bahlo, J; Böttcher, S; Cramer, P; Eichhorst, B; Engelke, A; Fink, AM; Fischer von Weikersthal, L; Fischer, K; Hallek, M; Hebart, H; Kneba, M; Kreuzer, KA; Langerbeins, P; Ritgen, M; Robrecht, S; Seiler, T; Stilgenbauer, S; Tausch, E; von Tresckow, J; Wendtner, CM | 1 |
| Balcerczak, E; Blonski, JZ; Borowiec, M; Karpinski, P; Korycka-Wolowiec, A; Lech-Maranda, E; Robak, T; Sasiadek, M; Wolowiec, D; Ziolkowska, E | 1 |
| Avigdor, A; Balasubramanian, S; Bartlett, NL; Chanan-Khan, A; Cramer, P; Demirkan, F; Dilhuydy, MS; Fraser, G; Goy, A; Grosicki, S; Hallek, M; Howes, A; Janssens, A; Karlsson, C; Loscertales, J; Mahler, M; Mayer, J; Panagiotidis, P; Pavlovsky, MA; Phelps, C; Pristupa, A; Pylypenko, H; Rule, S; Salman, M; Samoilova, O; Silva, RS; Sun, S; Villa, D | 1 |
| Beebe-Dimmer, JL; Ruterbusch, JJ; Schiffer, CA; Seymour, EK | 1 |
| Andersson, PO; Asklid, A; Bjellvi, J; Hansson, L; Johansson, H; Karlsson, C; Karlsson, K; Kimby, E; Klintman, J; Lauri, B; Mattsson, M; Norin, S; Österborg, A; Sandstedt, AB; Strandberg, M; Sylvan, SE; Tolvgård, S | 1 |
| Amador, V; Aymerich, M; Campo, E; Colomer, D; Delgado, J; Giró, A; Hanna, BS; Lee-Vergés, E; Lichter, P; López-Guerra, M; Pérez-Galán, P; Rodríguez, ML; Rodríguez, V; Rosich, L; Seiffert, M; Vidal-Crespo, A; Villamor, N; Yazdanparast, H | 1 |
| Sriwijitalai, W; Wiwanitkit, V | 1 |
| Abramson, JS; Barr, PM; Bartlett, NL; Blachly, JS; Booth, AM; Brander, DM; Brown, JR; Byrd, JC; Coutre, S; Ding, W; Erba, H; Fruth, B; Heerema, NA; Hurria, A; Kuzma, C; Larson, RA; Little, RF; Litzow, M; Lozanski, G; Major-Elechi, B; Mandrekar, SJ; Nattam, S; Owen, C; Ozer, HG; Parikh, SA; Rogers, KA; Ruppert, AS; Smith, SE; Stone, RM; Woyach, JA; Zhao, W | 1 |
| Khadwal, A; Lad, DP; Malhotra, P; Naseem, S; Prakash, G; Sachdeva, MS; Sreedharanunni, S; Tejaswi, V; Varma, N; Varma, S | 1 |
| Boyer, M; Eichhorst, B; Hillmen, P; Humphrey, K; Jiang, Y; Kater, AP; Kipps, TJ; Langerak, AW; Mobasher, M; Owen, C; Punnoose, EA; Seymour, JF; Verdugo, M; Wang, J; Wu, J | 1 |
| Al-Sawaf, O; Bahlo, J; Böttcher, S; Cramer, P; Eichhorst, BF; Estenfelder, S; Fink, AM; Fischer, K; Hallek, M; Illmer, T; Klaproth, H; Kreuzer, KA; Langerbeins, P; Ritgen, M; Robrecht, S; Stilgenbauer, S; von Tresckow, J; Wendtner, CM | 1 |
| Brown, JR; Eradat, H; Hirata, J; Kingsley, CD; Kipps, TJ; McIver, T; Morariu-Zamfir, R; O'Brien, S; Pagel, JM | 1 |
| Cmunt, E; Doubek, M; Hrobková, S; Karban, J; Mociková, H; Mohammadová, L; Molinský, J; Novák, J; Obrtlíková, P; Panovská, A; Šimkovič, M; Smolej, L; Špaček, M; Trněný, M | 1 |
| Liu, Z; Mandernach, MW; Markham, M | 1 |
| Ames, PR; Gentile, F; Merashli, M | 1 |
| Dreyling, M; Gafter-Gvili, A; Gurion, R; Shargian, L; Vidal, L | 1 |
| Avigdor, A; Bartlett, N; Cramer, P; de Jong, J; De Nicolao, G; Demirkan, F; Dilhuydy, MS; Fraser, G; Ganguly, S; Goy, A; Howes, A; Lavezzi, SM; Loscertales, J; Mahler, M; Neyens, M; Poggesi, I; Rule, S; Salman, M; Samoilova, O | 1 |
| Brychtova, Y; Brzobohata, A; Doubek, M; Mayer, J; Mraz, M; Panovska, A; Pavlova, S; Pospisilova, S; Skuhrova Francova, H; Spunarova, M; Tom, N; Trbusek, M | 1 |
| Abramson, JS; Amrein, PC; Armand, P; Brown, JR; Davids, MS; Fisher, DC; Hochberg, EP; Neuberg, D; Soumerai, JD; Werner, L | 1 |
| Andel, J; Baumann, M; Beyer, D; Burgstaller, S; Caligaris-Cappio, F; Dümmler, T; Foà, R; Frömming, A; Ghia, P; Gobbi, M; Janssens, A; Mauro, FR; Montillo, M; Riecke, K; Scarfò, L; Steurer, M; Trentin, L; Vauléon, S; Wildner, S | 1 |
| Abrisqueta, P; Bosch, F; Martínez, F; Pardos-Gea, J; Santamaría, A | 1 |
| Bogeljić Patekar, M; Kursar, M; Mandac Rogulj, I; Milunović, V; Mišura Jakobac, K; Ostojić Kolonić, S; Perica, D; Planinc-Peraica, A | 1 |
| Facco, M; Frezzato, F; Gurrieri, C; Imbergamo, S; Martini, V; Pagnin, E; Piazza, F; Pravato, S; Raggi, F; Scomazzon, E; Semenzato, G; Severin, F; Trentin, L; Trimarco, V; Visentin, A | 1 |
| Dreyling, M; Hallek, M; Knauf, W; Trümper, L | 1 |
| Di Bona, E; Finotto, S; Laveder, F; Paolini, R; Pomponi, F; Rodeghiero, F; Ruggeri, M; Sartori, R; Trentin, L; Visco, C | 1 |
| Lew, SQ; Shoji, J | 1 |
| Akinleye, A; Wu, M; Zhu, X | 1 |
| Ambrosetti, A; Castelli, M; Cortelazzo, S; Fanin, R; Isola, M; Mian, M; Nichele, I; Paolini, R; Pizzolo, G; Puglisi, S; Rodeghiero, F; Sancetta, R; Semenzato, G; Sissa, C; Trentin, L; Visco, C; Vivaldi, P; Volpetti, S; Zaja, F | 1 |
| Masood, N; Osmani, AH | 1 |
| Campeny-Najara, A; García, DK; García-Muñoz, R; Merchante-Andreu, M; Rabasa, P; Roldán-Galiacho, V | 1 |
| Ben-Yehuda, D; Gatt, ME; Goldschmidt, N; Gural, A | 1 |
| Beygi, H; Engle, R; Knopf, KB; Nordstrom, BL; Sterchele, JA; Teltsch, DY | 1 |
| Fesler, MJ; Hyder, MA; Parker, SM | 1 |
| Bowen, DA; Call, TG; Conte, M; Ding, W; Erlichman, C; Kay, NE; Kumar, S; Leis, JF; Lesnick, CE; Sassoon, TR; Secreto, C; Shanafelt, TD | 1 |
| Caimi, P; Habecker, B; Hill, BT; Kalaycio, M; Kindwall-Keller, T | 1 |
| Angelucci, E; Cascavilla, N; Chiarenza, A; Cortelezzi, A; Cuneo, A; Fabris, S; Foà, R; Giannarelli, D; Gobbi, M; Gritti, G; Guarini, A; Laurenti, L; Liberati, AM; Marasca, R; Mauro, FR; Morabito, F; Neri, A; Orsucci, L; Piciocchi, A; Reda, G; Rossi, D; Sciumè, M; Storti, S; Vignetti, M; Vincenti, D; Zaja, F | 1 |
| Dilley, RL; Gladstone, DE; Herman, JG; Karp, JE; McDevitt, MA; Poh, W; Pratz, KW; Showel, MM | 1 |
| Butrym, A; Dmoszynska, A; Dzietczenia, J; Gorska-Kosicka, M; Grzegorz, M; Hus, I; Jawniak, D; Jedrzejczak, WW; Krawczyk-Kulis, M; Kyrcz-Krzemien, S; Lech-Maranda, E; Poplawska, L; Walewski, J; Warzocha, K; Waszczuk-Gajda, A; Wrobel, T | 1 |
| Aoki, S | 1 |
| Abrisqueta, P; Bosch, F; Calpe, E; Carabia, J; Carpio, C; Castellví, J; Crespo, M; Palacio, C; Purroy, N | 1 |
| Abenhardt, W; Dörfel, S; Grugel, R; Hartmann, H; Knauf, W; Marschner, N; Meyer, D; Münz, M | 1 |
| Ayres, ML; Baladandayuthapani, V; El-Mabhouh, AA; Gandhi, V; Keating, MJ; Shpall, EJ; Wierda, WG | 1 |
| Dai, Q; Haddad, H; Mohammad, F | 1 |
| Cheng, H; Cheng, Z; Xie, F; Yu, P | 1 |
| Hamdan, A; Joyce, RM; Tzachanis, D; Uhlmann, EJ | 1 |
| Chanan-Khan, AA; Hallek, M; Howes, A; Kay, NE; Mahler, M; Osterborg, A; Salman, M; Sun, S; Wan, Y; Zhuang, SH | 1 |
| Boruchov, A; Mulay, S | 1 |
| Cheson, BD; Gehan, E; Ramzi, P; Ujjani, C; Wang, H; Wang, Y | 1 |
| Boehme, A; Brendel, K; Dreyling, M; Fingerle-Rowson, G; Fischer, R; Gonnermann, M; Höhler, T; Kegel, T; Kellermann, L; Nusch, A; Pönisch, W; Schmidt, C; Wendtner, C | 1 |
| García Muñoz, R; Izquierdo-Gil, A; Muñoz, A; Panizo, C; Rabasa, P; Roldan-Galiacho, V | 1 |
| Cascavilla, N; Coscia, M; De Paoli, L; Frustaci, AM; Gaidano, G; Gallamini, A; Ghia, P; Massaia, M; Montillo, M; Morra, E; Motta, M; Nichelatti, M; Orlandi, E; Petrizzi, VB; Rossi, D; Tedeschi, A | 1 |
| Byrd, JC; Flynn, JM; Johnson, AJ; Jones, JJ; Woyach, JA | 1 |
| Barosi, G; Billio, A; Brugiatelli, M; Ciolli, S; Cuneo, A; Laurenti, L; Marchetti, M; Mauro, FR; Molica, S; Montillo, M; Tura, S; Zinzani, P | 1 |
| Ahmed, S; Alousi, A; Anderlini, P; Bassett, RL; Ciurea, S; Gulbis, A; Jabbour, E; Khouri, IF; Korbling, M; Oran, B; Popat, UR; Rondon, G; Turturro, F; Wei, W | 1 |
| Cheson, BD | 3 |
| Becker, HJ; Beckmann, L; Brinkmann, K; Fandrey, J; Frenzel, LP; Hallek, M; Huelsemann, MF; Kashkar, H; Otto, T; Pallasch, CP; Patz, M; Reinhardt, HC; Theurich, S; von Bergwelt-Baildon, M; Wendtner, CM; Zahedi, RP | 1 |
| Dal Canton, A; Esposito, P; Gregorini, M; Libetta, C; Margiotta, E; Rampino, T | 1 |
| De Guibert, S; Delmer, A; Dupuis, J; Feugier, P; Guieze, R; Levy, V; Michallet, AS; Quinquenel, A; Royer, B; Willekens, C; Ysebaert, L | 1 |
| Burckhardt, G; Hagos, Y; Hundertmark, P; Marada, VV; Shnitsar, V; Wulf, G | 1 |
| Foltynski, P; Ladyzynski, P; Molik, M | 1 |
| Blonski, JZ; Cebula-Obrzut, B; Korycka-Wolowiec, A; Robak, T; Smolewski, P; Wolowiec, D; Ziolkowska, E | 1 |
| Alvarez-Mon, M; Antolin-Amerigo, D; Barbarroja-Escudero, J; Rodriguez-Rodriguez, M; Sanchez-Gonzalez, MJ | 1 |
| Arimany-Nardi, C; Campo, E; Colomer, D; Koepsell, H; Lee-Vergés, E; Montraveta, A; Pastor-Anglada, M; Puente, XS | 1 |
| Aimoto, M; Hirai, M; Inoue, A; Kameda, K; Kanashima, H; Kuno, M; Nakao, T; Yamane, T; Yoshida, M | 1 |
| Brown, JR; Eradat, H; Hirata, J; Kingsley, CD; Kipps, TJ; Lymp, J; O'Brien, S; Pagel, JM | 1 |
| Biriukova, LS; Dzhumbaeva, BT; Gemdzhian, EG; Kravchenko, SK; Melikian, AL; Roshtina, LS | 1 |
| Molica, S | 1 |
| Balakrishnan, K; Cervantes-Gomez, F; Gandhi, V; Keating, MJ; Lamothe, B; Wierda, WG; Woyach, JA | 1 |
| Assaily, W; Bence-Bruckler, I; Chamakhi, I; Christofides, A; Owen, C; Robinson, S; Toze, C | 1 |
| Berger, A; Brown, JR; Danilov, AV; Godbersen, JC; Paiva, C | 1 |
| Fiegl, M; Gastl, G; Kocher, F; Mian, M; Mondello, P; Ninkovic, M; Pircher, A; Steurer, M; Verdorfer, I; Waldthaler, C | 1 |
| Autore, F; Boncompagni, R; Bongarzoni, V; Borza, PA; Cantonetti, M; Cariccio, MR; Cervetti, G; Ciolli, S; Cortelezzi, A; D'Arena, G; Del Poeta, G; Efremov, DG; Foà, R; Ghio, F; Gozzetti, A; Innocenti, I; Laurenti, L; Mauro, FR; Mondello, P; Murru, R; Piccirillo, N; Pitini, V; Principe, MI; Reda, G; Sica, S; Vannata, B | 1 |
| Cramer, P; Eichhorst, B; Hallek, M; Langerbeins, P | 1 |
| Jallad, B; Mawri, S; Nabi, S; Won, J | 1 |
| Burger, JA; Estrov, Z; Ferrajoli, A; Jain, N; Keating, MJ; O'Brien, SM; Thompson, PA; Wang, X; Wierda, WG; Xiao, L | 1 |
| Bahlo, J; Bergmann, M; Binder, M; Böttcher, S; Cramer, P; Döhner, H; Dreyling, M; Eichhorst, B; Fink, AM; Fischer, K; Fischer, N; Gross-Ophoff, C; Hallek, M; Kluth, S; Kneba, M; Kreuzer, KA; Langerbeins, P; Maurer, C; Pflug, N; Rhein, C; Stilgenbauer, S; Tausch, E; Wendtner, CM | 1 |
| Avigdor, A; Balasubramanian, S; Bartlett, NL; Chanan-Khan, A; Cramer, P; Demirkan, F; Dilhuydy, MS; Fraser, G; Goy, A; Grosicki, S; Hallek, M; Howes, A; Janssens, A; Karlsson, C; Loscertales, J; Mahler, M; Mato, A; Mayer, J; Panagiotidis, P; Pavlovsky, MA; Phelps, C; Pristupa, A; Pylypenko, H; Rule, S; Salman, M; Samoilova, O; Silva, RS; Sun, S; Villa, D | 1 |
| Arimany-Nardí, C; Aymerich, M; Cabezas, S; Campo, E; Clot, G; Colomer, D; Jiménez, L; Lee-Vergés, E; López-Guerra, M; López-Guillermo, A; Montraveta, A; Pastor-Anglada, M; Pérez-Galán, P; Pinyol, M; Roldán, J; Rosich, L; Roué, G; Villamor, N; Xargay-Torrent, S | 1 |
| Autore, F; Bellesi, S; Chiusolo, P; Coscia, M; D'Arena, G; Efremov, DG; Innocenti, I; Laurenti, L; Mauro, FR; Mondello, P; Sica, S | 1 |
| Blank, J; Chang, JE; Eickhoff, J; Go, RS; Havighurst, T; Kahl, BS; Kim, K; Kirby-Slimp, R; Traynor, AM; Volk, LM; Weiss, M; Werndli, J | 1 |
| Bachow, SH; Lamanna, N | 1 |
| Biryukova, LS; Dzhumabaeva, BT; Golitsyna, EP; Varshavsky, VA | 1 |
| Böhme, A; Dreyling, M; Fries, S; Höhler, T; Kellermann, L; Kiewe, P; Zoellner, AK | 1 |
| Zahid, MF | 1 |
| Angrilli, F; Arcari, A; Caparrotti, G; Chiarenza, A; Ciolli, S; Coscia, M; De Paolis, MR; Di Raimondo, F; Di Renzo, N; Ferrara, F; Gentile, M; Giannotta, A; Giordano, A; Guarini, A; Herishanu, Y; Ilariucci, F; Levato, L; Mannina, D; Mastrullo, L; Mauro, FR; Mineo, G; Molica, S; Morabito, F; Murru, R; Musso, M; Musuraca, G; Orsucci, L; Polliack, A; Rago, A; Scortechini, I; Selleri, C; Shvidel, L; Tadmor, T; Tarantini, G; Tripepi, G; Villa, MR; Vincelli, I; Zinzani, PL; Zirlik, K | 1 |
| Bahlo, J; Cramer, P; Eichhorst, B; Engelke, A; Fink, AM; Fischer, K; Hallek, M; Kovacs, G; Langerbeins, P; Maurer, C; Müller, L; Pflug, N; Ritgen, M; Seiler, T; Stilgenbauer, S; von Tresckow, J; Wendtner, CM | 1 |
| Anwer, F; Kamal, MU; Riaz, IB; Segal, RJ | 1 |
| Bahlo, J; Böttcher, S; Busch, R; Döhner, H; Eichhorst, B; Fink, AM; Fischer, K; Gregor, M; Hallek, M; Kiehl, M; Klapper, W; Kneba, M; Köchling, G; Köppler, H; Kovacs, G; Kreuzer, KA; Lange, E; Maurer, C; Plesner, T; Plöger, C; Schlag, R; Sökler, M; Stilgenbauer, S; Trneny, M; Vehling-Kaiser, U; Wendtner, CM | 1 |
| Afanasyev, B; Barker, AM; Chang, CN; Domnikova, N; Doubek, M; Flinn, IW; Grosicki, S; Gupta, IV; Homenda, W; Janssens, A; Kuliczkowski, K; Offner, F; Panayiotidis, P; Smolej, L; West, SL; Wright, OJ | 1 |
| Günther, G; Kersting, M; Kleeberg, UR; Linde, H; Tessen, HW | 1 |
| Büchsel, M; Fleiner, M; Häcker, G; Pletschen, L; Serr, A | 1 |
| Altenhofer, P; Andel, J; Burcoveanu, C; Burgstaller, S; Doubek, M; Egle, A; Flochová, E; Fridrik, M; Gercheva, L; Girschikofsky, M; Greil, R; Hrubiško, M; Jäger, U; Klingler, A; Kozák, T; Králiková, E; Ladická, M; Mayer, J; Melchardt, T; Mihaylov, G; Mikušková, E; Nösslinger, T; Obrtlíková, P; Oexle, H; Palášthy, S; Papajík, T; Pecherstorfer, M; Petzer, A; Pleyer, L; Raynov, J; Smolej, L; Spasov, E; Stehlíková, O; Steurer, M; Zabernigg, A | 1 |
| Beaulieu, BB; Brown, JR; Danilov, AV; Findley, DL; Highhouse, B; Jones, SY; Lansigan, F; Lewis, LD; Roudaia, L | 1 |
| Ahmed, S; Alatrash, G; Anderlini, P; Bassett, RL; Burger, JA; Ciurea, SO; Ferrajoli, A; Gulbis, AM; Jabbour, EJ; Jorgensen, JL; Kadia, TM; Khouri, IF; Ledesma, C; Marin, D; Medeiros, LJ; Olson, A; Oran, B; Patel, KK; Popat, UR; Samuels, BI; Sui, D; Turturro, F | 1 |
| Allsup, D; Bloor, A; Collett, L; Hillmen, P; Hockaday, A; Howard, DR; Munir, T; Oughton, JB; Phillips, D; Rawstron, AC | 1 |
| Ayres, ML; Balakrishnan, K; Burger, JA; Cortes, JE; Ferrajoli, A; Gandhi, V; Jain, N; Kadia, TM; Keating, MJ; O'Brien, SM; Tambaro, FP; Wierda, WG | 1 |
| Banerji, V; Bouchard, ED; Gibson, SB; Johnston, JB; Katyal, S; Kost, SE; LaBossière, É; Liang, WS; Queau, ML; Ye, X | 1 |
| Derman, BA; Gashti, C; Jain, M; McAninch, EA | 1 |
| Cramer, P; Eichhorst, B; Hallek, M; Reinhardt, HC | 1 |
| Awan, FT; Byrd, JC; Eisenfeld, AJ; Garcia-Marco, JA; Hallek, M; Hebart, H; Hellmann, A; Hill, BT; Jaeger, U; Kloczko, J; Lech-Maranda, E; Loscertales, J; Mato, A; Pagel, JM; Robak, T; Stromatt, SC | 1 |
| Ando, K; Choi, I; Izutsu, K; Kiguchi, T; Ogawa, Y; Suzumiya, J; Takatsuka, Y | 1 |
| Balakrishnan, K; Gandhi, V; Keating, MJ; Modi, P; Wierda, WG; Yang, Q | 1 |
| Bach, C; Keating, MJ; Kirkpatrick, P; Yasothan, U | 1 |
| Rummel, MJ | 1 |
| Lin, TS | 1 |
| Campo, E; Colomer, D; López-Guerra, M; Milpied, P; Montserrat, E; Pérez-Galán, P; Roué, G; Villamor, N | 1 |
| Kalaycio, M | 1 |
| Ahmadi, T; Maniar, T; Schuster, S; Stadtmauer, E | 1 |
| Knauf, W | 1 |
| Masiello, D; Tulpule, A | 1 |
| Alonso, R; Bantia, S; Bontemps, F; Campo, E; Colomer, D; López-Guerra, M; Manz, C; Mehrling, T; Montserrat, E; Smal, C; Upshaw, R; Villamor, N | 1 |
| Aldaoud, A; Becker, M; Del Giudice, I; Fricke, HJ; Gercheva, L; Goranov, S; Herbrecht, R; Huguet, F; Juliusson, G; Klein, P; Knauf, WU; Liberati, A; Lissichkov, T; Loscertales, J; Merkle, K; Montillo, M; Postner, G; Tremmel, L | 1 |
| Friedberg, JW | 1 |
| Wilkes, GM | 1 |
| Glode, AE; Jarkowski, A | 1 |
| Hallek, M | 1 |
| Foon, KA; Hallek, MJ | 1 |
| Dennie, TW; Kolesar, JM | 1 |
| Cheson, BD; Dreyling, M; Friedberg, J; Gribben, J; Hoelzer, D; Knop, S; Montillo, M; Moreau, P; Pieper, A; Rummel, M; Wendtner, CM | 1 |
| Czuczman, MS; Elefante, A | 1 |
| Bauer, K; Brillant, C; Engert, A; Herbst, C; Kluge, S; Monsef, I; Skoetz, N | 1 |
| Brassac, M; Fournié, JJ; Gross, E; Kheirallah, S; L'Faqihi-Olive, FE; Laurent, G; Quillet-Mary, A; Struski, S; Ysebaert, L | 1 |
| Cheson, BD; Ujjani, C | 1 |
| Friesenhahn, V; Heymanns, J; Kleboth, K; Köppler, H; Mergenthaler, U; Thomalla, J; Weide, R | 1 |
| Montillo, M; Morra, E; Ricci, F; Tedeschi, A; Vismara, E | 1 |
| Cheson, B; Ujjani, C | 1 |
| Perez, K; Winer, ES | 1 |
| Augello, A; Bongarzoni, V; D'Arco, A; Di Renzo, N; Fazzi, R; Franco, G; Gentile, M; Iannitto, E; Mancuso, S; Marasca, R; Montanini, A; Morabito, F; Mulè, A; Musso, M; Musto, P; Pennese, E; Piccin, A; Rigacci, L; Rota-Scalabrini, D; Visani, G | 1 |
| Benn, P; Bilgrami, SF; Delach, JA; Kahl, BS; Kourelis, TV | 1 |
| Fiegl, M; Gastl, G; Hager, J; Oexle, H; Schnallinger, M; Schreieck, S; Stauder, R; Verdorfer, I; Waldthaler, C; Zabernigg, A; Zangerl, G | 1 |
| Gregory, SA; Rummel, MJ | 1 |
| Bahlo, J; Böttcher, S; Bühler, A; Busch, R; Cramer, P; Döhner, H; Eckart, MJ; Eichhorst, BF; Elter, T; Fischer, K; Goede, V; Hallek, M; Kiehl, M; Kneba, M; Kranz, G; Schweighofer, CD; Staib, P; Stilgenbauer, S; Wendtner, CM; Winkler, D | 1 |
| Ciucci, M; Dede, KA; Haskova, Z; Jonak, ZL; Lee, JM; Toso, JF; Trulli, SH; Whitacre, MN; White, JR | 1 |
| Belvisi, V; Cenfra, N; Cimino, G; Lichtner, M; Marocco, R; Mastroianni, CM; Mecarocci, S; Rago, A; Ridola, L | 1 |
| Arranz, R; Calleja, M; Cánovas, A; Cervera, JM; de la Fuente, I; de Oña, R; Domingo, E; Gironella, M; Gorosquieta, A; Grande, C; Guillén, H; Lopez-Lorenzo, JL; Marin, M; Medina, A; Mencha, C; Panizo, C; Peñalver, FJ; Perez, I; Perez, R; Prieto, E; Ramila, E; Salar, A; Sanchez-Gonzalez, B; Sancho, JM; Sebastian, E | 1 |
| Ganesan, P; Malipatil, B; Sagar, TG; Sundersingh, S | 1 |
| Gaertner, EM; Switlyk, SA | 1 |
| Fuss, H; Hallek, M; Hurtz, HJ; Knigge, O; Köppler, H; Losem, C; Reschke, D; Schmitz, S; Weide, R; Weiß, J | 1 |
| Chang, JE; Kahl, BS | 1 |
| Aldaoud, A; Becker, M; Del Giudice, I; Fricke, HJ; Gercheva, L; Goranov, S; Herbrecht, R; Huguet, F; Juliusson, G; Klein, P; Knauf, WU; Liberati, AM; Lissitchkov, T; Loscertales, J; Merkle, K; Montillo, M; Postner, G | 1 |
| Wierda, WG | 1 |
| Bahlo, J; Böttcher, S; Bühler, A; Busch, R; Cramer, P; Döhner, H; Eichhorst, BF; Fink, AM; Fischer, K; Goede, V; Hallek, M; Isfort, S; Kneba, M; Kreuzer, KA; Pflüger, KH; Ritgen, M; Schott, S; Schubert, J; Staib, P; Stilgenbauer, S; von Tresckow, J; Wendtner, CM; Winkler, D | 1 |
| Hoy, SM | 1 |
| Dreyling, M; Gafter-Gvili, A; Gurion, R; Raanani, P; Shpilberg, O; Vidal, L | 1 |
| Feiten, S; Friesenhahn, V; Heymanns, J; Kleboth, K; Köppler, H; Thomalla, J; van Roye, C; Weide, R | 1 |
| Eide, MJ; Mahmoud, BH | 1 |
| Balleisen, L; Eimermacher, H; Freier, W; Heit, W; Hinke, A; Ibach, S; Knauf, W; Megdenberg, D; Niederle, N; Weiß, J | 1 |
| Cheson, BD; Diehl, V | 1 |
| Chow, KU; Hoelzer, D; Mitrou, PS; Rummel, MJ; Weidmann, E | 1 |
| Schrijvers, D; Vermorken, JB | 1 |
| Aivado, M; Burger, J; Finke, J; Haas, R; Henze, L; Schulte, K | 1 |
| Bergmann, L; Hecker, T; Hübinger, G; Karakas, T; Rittgen, W; Schwänen, C; Wölfle, M | 1 |
| Bremer, K | 1 |
| Bergmann, M; Emmerich, B; Fingerle-Rowson, G; Goede, V; Hallek, M; Schmitt, B; Schweighofer, C; Wendtner, CM | 1 |
| Eichhorst, BF; Hallek, MJ; Wendtner, CM | 1 |
| Heymanns, J; Köppler, H; Pandorf, A; Weide, R | 2 |
| Arzberger, H; Boewer, C; Bremer, K; Dachselt, K; Franke, A; Freund, M; Fricke, HJ; Hahnfeld, S; Herold, M; Ismer, B; Klinkenstein, C; Müller, C; Niederwieser, D; Pasold, R; Richter, P; Schirmer, V; Schulze, A; Schulze, M; Schwarzer, A; Weniger, J; Winkelmann, C | 1 |
| Ferrajoli, A | 1 |
| Bergmann, MA; Boening, L; Emmerich, B; Goebeler, ME; Hallek, MJ; Herold, M; Ruelfs, C; Wilhelm, M | 1 |
| Arnaudov, G; Lissitchkov, T; Merkle, Kh; Peytchev, D | 1 |
| Adam, K; Bergmann, J; Buchheidt, D; Hehlmann, R; Hummel, M; Reiter, S | 1 |
| Bartel, C; Geiger, H; Hauser, IA; Obermüller, N; Rummel, MJ | 1 |
| Traynor, K | 1 |
| Blumenstengel, K; Fricke, HJ; Höffken, K; Kath, R | 1 |
| Böhme, A; Hoelzer, D; Koschmieder, S; Seipelt, G | 1 |
| Boehrer, S; Chow, KU; Geduldig, K; Hoelzer, D; Krapohl, A; Mitrou, PS; Weidmann, E | 1 |
| Boehrer, S; Chow, KU; Hoelzer, D; Mitrou, PS; Rummel, MJ; Schneider, B; Seipelt, G; Sommerlad, WD; Weidmann, E | 1 |
| Gores, A; Heymanns, J; Köppler, H; Weide, R | 1 |
43 review(s) available for bendamustine hydrochloride and Leukemia, Lymphocytic, Chronic, B-Cell
| Article | Year |
|---|---|
Novel Therapies for Follicular Lymphoma and Other Indolent Non-Hodgkin Lymphomas.
Topics: Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Cyclophosphamide; Doxorubicin; Humans; Immunotherapy, Adoptive; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, B-Cell, Marginal Zone; Lymphoma, Follicular; Lymphoma, Non-Hodgkin; Prednisone; Receptors, Chimeric Antigen; Risk Assessment; Rituximab; Stem Cell Transplantation; Vincristine; Waldenstrom Macroglobulinemia | 2021 |
Bendamustine: A review of pharmacology, clinical use and immunological effects (Review).
Topics: Antineoplastic Agents; Bendamustine Hydrochloride; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, B-Cell; Nitrogen Mustard Compounds | 2022 |
Efficacy and Safety of Bendamustine and Ibrutinib in Previously Untreated Patients With Chronic Lymphocytic Leukemia: Indirect Comparison.
Topics: Adenine; Antineoplastic Agents; Bendamustine Hydrochloride; Disease-Free Survival; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Piperidines; Pyrazoles; Pyrimidines; Treatment Outcome | 2017 |
Bendamustine hydrochloride in patients with B-cell malignancies who have comorbidities - is there an optimal dose?
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Clinical Trials as Topic; Comorbidity; Humans; Leukemia, B-Cell; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, B-Cell; Lymphoma, Non-Hodgkin; Treatment Outcome | 2017 |
Fatal Cache Valley virus meningoencephalitis associated with rituximab maintenance therapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Atrophy; Autoimmune Diseases of the Nervous System; B-Lymphocytes; Bendamustine Hydrochloride; Brain; Bunyamwera virus; Bunyaviridae Infections; Diagnosis, Differential; Fatal Outcome; Gliosis; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Magnetic Resonance Imaging; Maintenance Chemotherapy; Male; Meningoencephalitis; Middle Aged; Paraneoplastic Syndromes, Nervous System; Rituximab | 2018 |
Bendamustine for patients with indolent B cell lymphoproliferative malignancies including chronic lymphocytic leukaemia - an updated meta-analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; B-Lymphocytes; Bendamustine Hydrochloride; Chlorambucil; Cyclophosphamide; Disease-Free Survival; Doxorubicin; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, B-Cell; Maintenance Chemotherapy; Prednisone; Randomized Controlled Trials as Topic; Survival Rate; Vincristine | 2019 |
BENDAMUSTINE: AN OLD DRUG IN THE NEW ERA FOR PATIENTS WITH NON-HODGKIN LYMPHOMAS AND CHRONIC LYMPHOCYTIC LEUKEMIA.
Topics: Adult; Antineoplastic Agents, Alkylating; Bendamustine Hydrochloride; Child; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Non-Hodgkin; Medication Therapy Management | 2018 |
Novel agents for chronic lymphocytic leukemia.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Humans; Lenalidomide; Leukemia, Lymphocytic, Chronic, B-Cell; Nitrogen Mustard Compounds; Thalidomide | 2013 |
Bendamustine and rituximab for indolent B-cell non-hodgkin lymphoma in patients with compensated hepatitis C cirrhosis: a case series.
Topics: Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Female; Hepatitis C, Chronic; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Liver Cirrhosis; Lymphoma, B-Cell; Lymphoma, Follicular; Middle Aged; Nitrogen Mustard Compounds; Rituximab; Treatment Outcome | 2013 |
[Chronic lymphocytic leukemia].
Topics: Adenine; Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Cyclophosphamide; Doxorubicin; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Nitrogen Mustard Compounds; Piperidines; Practice Guidelines as Topic; Prednisone; Pyrazoles; Pyrimidines; Rituximab; Vidarabine; Vincristine | 2014 |
Bendamustine-induced immune hemolytic anemia in a chronic lymphocytic leukemia patient: A case report and review of the literature.
Topics: Aged; Anemia, Hemolytic; Bendamustine Hydrochloride; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Nitrogen Mustard Compounds | 2014 |
Entering the era of targeted therapy for chronic lymphocytic leukemia: impact on the practicing clinician.
Topics: Adenine; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Chlorambucil; Cyclophosphamide; Drug Resistance, Neoplasm; Gene Deletion; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Molecular Targeted Therapy; Nitrogen Mustard Compounds; Piperidines; Practice Patterns, Physicians'; Purines; Pyrazoles; Pyrimidines; Quinazolinones; Vidarabine | 2014 |
A network meta-analysis of progression free survival and overall survival in first-line treatment of chronic lymphocytic leukemia.
Topics: Age Factors; Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Bayes Theorem; Bendamustine Hydrochloride; Chlorambucil; Cyclophosphamide; Disease-Free Survival; Humans; Kaplan-Meier Estimate; Leukemia, Lymphocytic, Chronic, B-Cell; Markov Chains; Nitrogen Mustard Compounds; Pentostatin; Physical Fitness; Proportional Hazards Models; Randomized Controlled Trials as Topic; Rituximab; Vidarabine | 2015 |
[Alleviated anemia by bendamustine in cold agglutinin disease associated with small lymphocytic lymphoma].
Topics: Aged; Anemia, Hemolytic, Autoimmune; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Nitrogen Mustard Compounds; Rituximab; Treatment Outcome | 2015 |
A canadian perspective on the first-line treatment of chronic lymphocytic leukemia.
Topics: Adenine; Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Canada; Chlorambucil; Cyclophosphamide; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Piperidines; Pyrazoles; Pyrimidines; Rituximab; Vidarabine | 2015 |
Advances in first-line treatment of chronic lymphocytic leukemia: current recommendations on management and first-line treatment by the German CLL Study Group (GCLLSG).
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Chromosome Deletion; Chromosomes, Human, Pair 17; Cyclophosphamide; Female; Germany; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Practice Guidelines as Topic; Rituximab; Tumor Suppressor Protein p53; Vidarabine | 2016 |
Evolving Strategies for the Treatment of Chronic Lymphocytic Leukemia in the Upfront Setting.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Humans; Immunotherapy; Leukemia, Lymphocytic, Chronic, B-Cell; Protein Kinase Inhibitors; Rituximab | 2016 |
Bendamustin-Rituximab Combination Is a Safe and Effective, Ambulatory Treatment for Elderly Patients with Chronic Lymphocytic Leukemia: Retrospective Real-world Analysis by Age from a German Registry and Review of the Literature.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Retrospective Studies; Rituximab | 2016 |
Current strategies to create tailored and risk-adapted therapies for CLL patients.
Topics: Adenine; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Bridged Bicyclo Compounds, Heterocyclic; Clinical Trials, Phase II as Topic; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Piperidines; Precision Medicine; Purines; Pyrazoles; Pyrimidines; Quinazolinones; Risk Factors; Sulfonamides | 2016 |
Bendamustine in chronic lymphocytic leukemia and refractory lymphoma.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Drug Resistance, Neoplasm; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma; Nitrogen Mustard Compounds; Randomized Controlled Trials as Topic; Rituximab; Treatment Outcome | 2008 |
Novel agents in chronic lymphocytic leukemia: efficacy and tolerability of new therapies.
Topics: Antineoplastic Agents; Bendamustine Hydrochloride; Flavonoids; Humans; Indoles; Lenalidomide; Leukemia, Lymphocytic, Chronic, B-Cell; Maximum Tolerated Dose; Nitrogen Mustard Compounds; Piperidines; Pyrroles; Thalidomide; Thionucleotides; Treatment Outcome | 2008 |
Bendamustine: a new look at an old drug.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Drug Resistance, Neoplasm; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma; Lymphoproliferative Disorders; Nitrogen Mustard Compounds | 2009 |
Chronic lymphocytic leukemia: new concepts and emerging therapies.
Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; B-Lymphocyte Subsets; Bendamustine Hydrochloride; CD5 Antigens; Disease Progression; Drugs, Investigational; Humans; Immunologic Factors; Immunotherapy; Leukemia, Lymphocytic, Chronic, B-Cell; Multicenter Studies as Topic; Neoplasm, Residual; Nitrogen Mustard Compounds; Prognosis; Randomized Controlled Trials as Topic; Salvage Therapy | 2009 |
Bendamustine in the treatment of chronic lymphocytic leukemia.
Topics: Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Chlorambucil; Clinical Trials as Topic; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Leukopenia; Nitrogen Mustard Compounds; Treatment Outcome | 2009 |
Bendamustine therapy in chronic lymphocytic leukemia.
Topics: Antineoplastic Agents; Bendamustine Hydrochloride; Drug Tolerance; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Non-Hodgkin; Neoplasms; Nitrogen Mustard Compounds | 2009 |
Bendamustine: a new treatment option for chronic lymphocytic leukemia.
Topics: Aged; Antineoplastic Agents; Bendamustine Hydrochloride; Clinical Trials as Topic; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Molecular Structure; Nitrogen Mustard Compounds; Treatment Outcome | 2009 |
State-of-the-art treatment of chronic lymphocytic leukemia.
Topics: Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antibodies, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Cell Cycle; Combined Modality Therapy; Cytostatic Agents; Hematopoietic Stem Cell Transplantation; Humans; Immunotherapy; Leukemia, Lymphocytic, Chronic, B-Cell; Neoplasm, Residual; Nitrogen Mustard Compounds; Randomized Controlled Trials as Topic; Rituximab; Salvage Therapy; Thionucleotides; Transplantation, Homologous; Vidarabine | 2009 |
Changing paradigms in the treatment of chronic lymphocytic leukemia.
Topics: Antibodies, Monoclonal; Antineoplastic Agents, Alkylating; Bendamustine Hydrochloride; Cyclophosphamide; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Nitrogen Mustard Compounds; Prognosis; Purines | 2010 |
Bendamustine for the treatment of chronic lymphocytic leukemia and rituximab-refractory, indolent B-cell non-Hodgkin lymphoma.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Bendamustine Hydrochloride; Drug Administration Schedule; Drug Resistance, Neoplasm; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, B-Cell; Nitrogen Mustard Compounds; Rituximab | 2009 |
Optimal use of bendamustine in chronic lymphocytic leukemia, non-Hodgkin lymphomas, and multiple myeloma: treatment recommendations from an international consensus panel.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Drug Administration Schedule; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Non-Hodgkin; Multiple Myeloma; Nitrogen Mustard Compounds | 2010 |
Bendamustine for the treatment of indolent non-Hodgkin's lymphoma and chronic lymphocytic leukemia.
Topics: Antineoplastic Agents; Bendamustine Hydrochloride; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Non-Hodgkin; Nitrogen Mustard Compounds | 2010 |
Bendamustine in chronic lymphocytic leukemia and non-Hodgkin's lymphoma.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Clinical Trials as Topic; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Non-Hodgkin; Nitrogen Mustard Compounds | 2010 |
Bendamustine: new perspective for an old drug in lymphoproliferative disorders.
Topics: Antineoplastic Agents; Bendamustine Hydrochloride; Clinical Trials as Topic; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Non-Hodgkin; Lymphoproliferative Disorders; Nitrogen Mustard Compounds | 2010 |
Chronic lymphocytic leukemia: something old, something new and something borrowed...
Topics: Antibodies, Monoclonal; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Chlorambucil; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Neoplasm Staging; Nitrogen Mustard Compounds; Prognosis; Randomized Controlled Trials as Topic; Recurrence | 2011 |
Bendamustine's emerging role in the management of lymphoid malignancies.
Topics: Animals; Antineoplastic Agents, Alkylating; Bendamustine Hydrochloride; Clinical Trials as Topic; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma; Lymphoma, Follicular; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Mantle-Cell; Nitrogen Mustard Compounds | 2011 |
Cutaneous granulomatous vasculitis associated with chronic lymphocytic leukemia: case report and review of literature of a rare entity.
Topics: Aged; Anti-Inflammatory Agents; Antineoplastic Agents; Bendamustine Hydrochloride; Biopsy; Erythrocyte Transfusion; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Nitrogen Mustard Compounds; Paraneoplastic Syndromes; Prednisone; Skin Diseases, Vascular; Treatment Outcome; Vasculitis | 2012 |
Bendamustine for treatment of chronic lymphocytic leukemia.
Topics: Antineoplastic Agents, Alkylating; Bendamustine Hydrochloride; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Nitrogen Mustard Compounds | 2012 |
Bendamustine: a review of its use in the management of chronic lymphocytic leukaemia, rituximab-refractory indolent non-Hodgkin's lymphoma and multiple myeloma.
Topics: Antineoplastic Agents, Alkylating; Bendamustine Hydrochloride; Disease-Free Survival; Dose-Response Relationship, Drug; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Non-Hodgkin; Multiple Myeloma; Nitrogen Mustard Compounds; Randomized Controlled Trials as Topic; Retrospective Studies | 2012 |
Bendamustine for patients with indolent B cell lymphoid malignancies including chronic lymphocytic leukaemia.
Topics: Adult; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Cyclophosphamide; Doxorubicin; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, B-Cell; Lymphoma, Follicular; Lymphoma, Mantle-Cell; Nitrogen Mustard Compounds; Prednisone; Recurrence; Vincristine; Waldenstrom Macroglobulinemia | 2012 |
Phase I studies with bendamustine: an update.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Drug Administration Schedule; Europe; Hematologic Neoplasms; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma; Lymphopenia; Multiple Myeloma; Nitrogen Mustard Compounds; Research Design | 2002 |
Hematologic malignancies: new developments and future treatments.
Topics: Adenine Nucleotides; Alemtuzumab; Alkaloids; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antibodies, Neoplasm; Antineoplastic Agents; Apoptosis; Arabinonucleosides; Bendamustine Hydrochloride; Boronic Acids; Bortezomib; Cell Cycle; Cell Survival; Clofarabine; Cytosine; Dioxolanes; Flavonoids; Hematologic Neoplasms; Humans; Immunoconjugates; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma; Lymphoma, Non-Hodgkin; Multiple Myeloma; NF-kappa B; Nitrogen Mustard Compounds; Oligonucleotides, Antisense; Peptide Hydrolases; Piperidines; Protease Inhibitors; Proteasome Endopeptidase Complex; Pyrazines; Remission Induction; Rituximab; Staurosporine; Thionucleotides | 2002 |
[Current concepts in chronic lymphocytic leukemia. Better chances for young patients].
Topics: Age Factors; Aged; Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antibodies, Neoplasm; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Chlorambucil; Combined Modality Therapy; Enzyme Inhibitors; Humans; Immunosuppressive Agents; Leukemia, Lymphocytic, Chronic, B-Cell; Middle Aged; Nitrogen Mustard Compounds; Radiotherapy Dosage; Randomized Controlled Trials as Topic; Risk Factors; Rituximab; Time Factors; Vidarabine | 2003 |
Advances in chemotherapy for chronic lymphocytic leukemia.
Topics: Alkylating Agents; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Drug Therapy; Hematopoietic Cell Growth Factors; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Nitrogen Mustard Compounds; Purines | 2004 |
65 trial(s) available for bendamustine hydrochloride and Leukemia, Lymphocytic, Chronic, B-Cell
| Article | Year |
|---|---|
Improvements in Health-related Quality of Life and Symptoms in Patients With Previously Untreated Chronic Lymphocytic Leukemia: Final Results From the Phase II GIBB Study of the Combination of Obinutuzumab and Bendamustine.
Topics: Antibodies, Monoclonal, Humanized; Bendamustine Hydrochloride; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Quality of Life; Surveys and Questionnaires | 2022 |
Bendamustine versus chlorambucil in treatment of chronic lymphocytic leukaemia in China: a randomized, open-label, parallel-controlled, phase III clinical trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Chlorambucil; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Progression-Free Survival | 2022 |
Enduring undetectable MRD and updated outcomes in relapsed/refractory CLL after fixed-duration venetoclax-rituximab.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Bridged Bicyclo Compounds, Heterocyclic; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Neoplasm, Residual; Recurrence; Rituximab; Sulfonamides | 2022 |
Obinutuzumab, acalabrutinib, and venetoclax, after an optional debulking with bendamustine in relapsed or refractory chronic lymphocytic leukaemia (CLL2-BAAG): a multicentre, open-label, phase 2 trial.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Benzamides; Bridged Bicyclo Compounds, Heterocyclic; Cytoreduction Surgical Procedures; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Neoplasm, Residual; Proto-Oncogene Proteins c-bcl-2; Pyrazines; Sulfonamides | 2022 |
First-Line Venetoclax Combinations in Chronic Lymphocytic Leukemia.
Topics: Antineoplastic Agents; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Bridged Bicyclo Compounds, Heterocyclic; Cyclophosphamide; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Neoplasm, Residual; Rituximab | 2023 |
Obinutuzumab plus bendamustine for relapsed/refractory chronic lymphocytic leukemia and predictive and prognostic impact of genetic alterations: the phase II GABRIELL study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, B-Cell; Prognosis; Recurrence; Rituximab | 2023 |
Idelalisib addition has neutral to beneficial effects on quality of life in bendamustine/rituximab-treated patients: results of a phase 3, randomized, controlled trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Double-Blind Method; Female; Humans; Kaplan-Meier Estimate; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Purines; Quality of Life; Quinazolinones; Rituximab | 2019 |
Bendamustine, followed by ofatumumab and ibrutinib in chronic lymphocytic leukemia (CLL2-BIO): primary endpoint analysis of a multicenter, open-label phase-II trial.
Topics: Adenine; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Piperidines; Treatment Outcome | 2021 |
ASCEND: Phase III, Randomized Trial of Acalabrutinib Versus Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Benzamides; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Neoplasm Staging; Progression-Free Survival; Purines; Pyrazines; Quinazolinones; Rituximab | 2020 |
Final 5-year findings from the phase 3 HELIOS study of ibrutinib plus bendamustine and rituximab in patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma.
Topics: Adenine; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Piperidines; Rituximab | 2020 |
Venetoclax plus bendamustine-rituximab or bendamustine-obinutuzumab in chronic lymphocytic leukemia: final results of a phase 1b study (GO28440).
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Bridged Bicyclo Compounds, Heterocyclic; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Rituximab; Sulfonamides | 2021 |
Safety and efficacy of obinutuzumab alone or with chemotherapy in previously untreated or relapsed/refractory chronic lymphocytic leukaemia patients: Final analysis of the Phase IIIb GREEN study.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Biomarkers, Pharmacological; Chlorambucil; Cyclophosphamide; Female; Humans; Immunoglobulin Heavy Chains; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Neoplasm, Residual; Neutropenia; Non-Randomized Controlled Trials as Topic; Progression-Free Survival; Recurrence; Safety; Thrombocytopenia; Treatment Outcome; Vidarabine | 2021 |
COSMIC, chemotherapy plus ofatumumab at standard or mega-dose in chronic lymphocytic leukaemia, a phase II randomised study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Cyclophosphamide; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Treatment Outcome; Vidarabine | 2021 |
Durable remissions following combined targeted therapy in patients with CLL harboring TP53 deletions and/or mutations.
Topics: Adenine; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Bridged Bicyclo Compounds, Heterocyclic; Female; Gene Deletion; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Mutation; Piperidines; Progression-Free Survival; Prospective Studies; Sulfonamides; Tumor Suppressor Protein p53 | 2021 |
Adverse event burden in older patients with CLL receiving bendamustine plus rituximab or ibrutinib regimens: Alliance A041202.
Topics: Adenine; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Atrial Fibrillation; Bendamustine Hydrochloride; Female; Follow-Up Studies; Humans; Hypertension; Infections; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Piperidines; Prognosis; Rituximab; Survival Rate | 2021 |
A Prospective Economic Analysis of Early Outcome Data From the Alliance A041202/ CCTG CLC.2 Randomized Phase III Trial Of Bendamustine-Rituximab Compared With Ibrutinib-Based Regimens in Untreated Older Patients With Chronic Lymphocytic Leukemia.
Topics: Adenine; Aged; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Piperidines; Prospective Studies; Rituximab; Survival Analysis; Treatment Outcome | 2021 |
Akt inhibitor MK-2206 in combination with bendamustine and rituximab in relapsed or refractory chronic lymphocytic leukemia: Results from the N1087 alliance study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Heterocyclic Compounds, 3-Ring; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Neoplasm Staging; Recurrence; Retreatment; Rituximab; Survival Analysis; Treatment Outcome | 2017 |
Safety and Pharmacokinetics of Bendamustine Rapid-Infusion Formulation.
Topics: Adult; Aged; Aged, 80 and over; Area Under Curve; Bendamustine Hydrochloride; Biological Availability; Chemistry, Pharmaceutical; Cross-Over Studies; Female; Humans; Injection Site Reaction; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Non-Hodgkin; Male; Middle Aged; Therapeutic Equivalency | 2017 |
Improvement of fatigue, physical functioning, and well-being among patients with severe impairment at baseline receiving ibrutinib in combination with bendamustine and rituximab for relapsed chronic lymphocytic leukemia/small lymphocytic lymphoma in the H
Topics: Adenine; Aged; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Double-Blind Method; Fatigue; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Neoplasm Recurrence, Local; Outcome Assessment, Health Care; Physical Fitness; Piperidines; Pyrazoles; Pyrimidines; Quality of Life; Rituximab; Surveys and Questionnaires | 2018 |
Rituximab plus bendamustine or chlorambucil for chronic lymphocytic leukemia: primary analysis of the randomized, open-label MABLE study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Chlorambucil; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Remission Induction; Rituximab; Survival Analysis; Treatment Outcome | 2018 |
CLL2-BXX Phase II trials: sequential, targeted treatment for eradication of minimal residual disease in chronic lymphocytic leukemia.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Bone Marrow; Bridged Bicyclo Compounds, Heterocyclic; Humans; Induction Chemotherapy; Leukemia, Lymphocytic, Chronic, B-Cell; Maintenance Chemotherapy; Molecular Targeted Therapy; Neoplasm, Residual; Purines; Quinazolinones; Sulfonamides; Treatment Outcome | 2018 |
Venetoclax-Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Bridged Bicyclo Compounds, Heterocyclic; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Humans; Kaplan-Meier Estimate; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Neoplasm, Residual; Neutropenia; Recurrence; Rituximab; Sulfonamides; Tumor Lysis Syndrome; Young Adult | 2018 |
Obinutuzumab plus bendamustine in previously untreated patients with CLL: a subgroup analysis of the GREEN study.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm, Residual; Prognosis; Remission Induction; Rituximab; Salvage Therapy; Survival Rate | 2018 |
Safety of obinutuzumab alone or combined with chemotherapy for previously untreated or relapsed/refractory chronic lymphocytic leukemia in the phase IIIb GREEN study.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Chlorambucil; Cyclophosphamide; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Vidarabine | 2018 |
Bendamustine followed by obinutuzumab and venetoclax in chronic lymphocytic leukaemia (CLL2-BAG): primary endpoint analysis of a multicentre, open-label, phase 2 trial.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Bridged Bicyclo Compounds, Heterocyclic; Drug Administration Schedule; Female; Germany; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Prospective Studies; Sulfonamides; Time Factors; Treatment Outcome | 2018 |
Updated results from the phase 3 HELIOS study of ibrutinib, bendamustine, and rituximab in relapsed chronic lymphocytic leukemia/small lymphocytic lymphoma.
Topics: Adenine; Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Double-Blind Method; Female; Follow-Up Studies; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Piperidines; Prognosis; Pyrazoles; Pyrimidines; Rituximab; Survival Rate; Young Adult | 2019 |
First-line therapy in chronic lymphocytic leukemia: a Swedish nation-wide real-world study on 1053 consecutive patients treated between 2007 and 2013.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Chlorambucil; Chromosome Deletion; Chromosomes, Human, Pair 17; Cyclophosphamide; Disease-Free Survival; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Prednisolone; Registries; Retrospective Studies; Rituximab; Survival Rate; Sweden; Vidarabine | 2019 |
Ibrutinib Regimens versus Chemoimmunotherapy in Older Patients with Untreated CLL.
Topics: Adenine; Aged; Aged, 80 and over; Bendamustine Hydrochloride; Drug Therapy, Combination; Female; Follow-Up Studies; Hematologic Diseases; Humans; Immunotherapy; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Piperidines; Progression-Free Survival; Pyrazoles; Pyrimidines; Rituximab; Survival Analysis | 2018 |
Fixed Duration of Venetoclax-Rituximab in Relapsed/Refractory Chronic Lymphocytic Leukemia Eradicates Minimal Residual Disease and Prolongs Survival: Post-Treatment Follow-Up of the MURANO Phase III Study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Bridged Bicyclo Compounds, Heterocyclic; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Neoplasm, Residual; Progression-Free Survival; Recurrence; Rituximab; Sulfonamides; Time Factors | 2019 |
Systemic Exposure of Rituximab Increased by Ibrutinib: Pharmacokinetic Results and Modeling Based on the HELIOS Trial.
Topics: Adenine; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Models, Biological; Piperidines; Pyrazoles; Pyrimidines; Rituximab; Treatment Outcome | 2019 |
Phase 1 study of lenalidomide, bendamustine, and rituximab in previously untreated patients with chronic lymphocytic leukemia.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Drug Administration Schedule; Female; Humans; Lenalidomide; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Neoplasm Staging; Prognosis; Remission Induction; Rituximab; Treatment Outcome | 2019 |
Olaptesed pegol (NOX-A12) with bendamustine and rituximab: a phase IIa study in patients with relapsed/refractory chronic lymphocytic leukemia.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Aptamers, Nucleotide; Bendamustine Hydrochloride; Disease-Free Survival; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Recurrence; Rituximab; Survival Rate | 2019 |
Bendamustine in combination with ofatumumab in relapsed or refractory chronic lymphocytic leukemia: a GIMEMA Multicenter Phase II Trial.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Nitrogen Mustard Compounds; Recurrence | 2014 |
The HELIOS trial protocol: a phase III study of ibrutinib in combination with bendamustine and rituximab in relapsed/refractory chronic lymphocytic leukemia.
Topics: Adenine; Administration, Oral; Adolescent; Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Female; Humans; Kaplan-Meier Estimate; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Nitrogen Mustard Compounds; Piperidines; Pyrazoles; Pyrimidines; Rituximab | 2015 |
Ofatumumab and bendamustine in previously treated chronic lymphocytic leukemia and small lymphocytic lymphoma.
Topics: Aged; Aged, 80 and over; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Disease-Free Survival; Drug Administration Schedule; Fatigue; Female; Humans; Infections; Infusions, Intraventricular; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Neutropenia; Retreatment; Treatment Outcome | 2015 |
BFR (bendamustine, fludarabine, and rituximab) allogeneic conditioning for chronic lymphocytic leukemia/lymphoma: reduced myelosuppression and GVHD.
Topics: Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Bendamustine Hydrochloride; Combined Modality Therapy; Drug Combinations; Female; Graft vs Host Disease; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma; Male; Middle Aged; Nitrogen Mustard Compounds; Recurrence; Rituximab; Transplantation Conditioning; Transplantation, Homologous; Vidarabine | 2014 |
Obinutuzumab plus fludarabine/cyclophosphamide or bendamustine in the initial therapy of CLL patients: the phase 1b GALTON trial.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Cyclophosphamide; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Neoadjuvant Therapy; Nitrogen Mustard Compounds; Treatment Outcome; Vidarabine | 2015 |
[Chronic lymphocytic leukemia accompanied by renal failure].
Topics: Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Bendamustine Hydrochloride; Drug Therapy, Combination; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Nitrogen Mustard Compounds; Pilot Projects; Renal Insufficiency; Rituximab; Treatment Outcome | 2014 |
Bendamustine and rituximab in combination with lenalidomide in patients with chronic lymphocytic leukemia.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Chromosome Aberrations; Drug Administration Schedule; Female; Humans; Lenalidomide; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Maximum Tolerated Dose; Middle Aged; Mutation; Neoplasm Staging; Prognosis; Rituximab; Thalidomide; Treatment Outcome | 2016 |
Ibrutinib combined with bendamustine and rituximab compared with placebo, bendamustine, and rituximab for previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (HELIOS): a randomised, double-blind, phase 3 study.
Topics: Adenine; Adult; Aged; Aged, 80 and over; Anemia; Antineoplastic Combined Chemotherapy Protocols; Atrial Fibrillation; Bendamustine Hydrochloride; Disease Progression; Disease-Free Survival; Double-Blind Method; Female; Hemorrhage; Humans; Intention to Treat Analysis; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Nausea; Neutropenia; Piperidines; Pyrazoles; Pyrimidines; Retreatment; Rituximab; Thrombocytopenia | 2016 |
Bendamustine + rituximab chemoimmunotherapy and maintenance lenalidomide in relapsed, refractory chronic lymphocytic leukaemia and small lymphocytic lymphoma: A Wisconsin Oncology Network Study.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Disease Progression; Disease-Free Survival; Female; Humans; Lenalidomide; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Recurrence; Remission Induction; Rituximab; Thalidomide; Treatment Outcome | 2016 |
Effect of first-line treatment on second primary malignancies and Richter's transformation in patients with CLL.
Topics: Adult; Aged; Aged, 80 and over; Bendamustine Hydrochloride; Case-Control Studies; Cell Transformation, Neoplastic; Chlorambucil; Cyclophosphamide; Disease-Free Survival; Female; Germany; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Neoplasms, Second Primary; Registries; Risk Assessment; Risk Factors; Vidarabine | 2016 |
First-line chemoimmunotherapy with bendamustine and rituximab versus fludarabine, cyclophosphamide, and rituximab in patients with advanced chronic lymphocytic leukaemia (CLL10): an international, open-label, randomised, phase 3, non-inferiority trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Cyclophosphamide; Female; Follow-Up Studies; Humans; Immunotherapy; International Agencies; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Neoplasm Staging; Prognosis; Rituximab; Survival Rate; Vidarabine | 2016 |
A phase 2, multicenter study investigating ofatumumab and bendamustine combination in patients with untreated or relapsed CLL.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Disease-Free Survival; Drug Administration Schedule; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Recurrence; Remission Induction; Treatment Outcome | 2016 |
Rituximab maintenance versus observation alone in patients with chronic lymphocytic leukaemia who respond to first-line or second-line rituximab-containing chemoimmunotherapy: final results of the AGMT CLL-8a Mabtenance randomised trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Cyclophosphamide; Female; Humans; Immunotherapy; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Neoplasm Staging; Remission Induction; Rituximab; Survival Rate; Vidarabine | 2016 |
A phase I dose-ranging study of bendamustine and rituximab in chronic lymphocytic leukemia patients with comorbidities.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Comorbidity; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Rituximab; Treatment Outcome | 2017 |
Chemotherapy plus Ofatumumab at Standard or Mega dose in relapsed CLL (COSMIC) trial: study protocol for a phase II randomised controlled trial.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Clinical Protocols; Cyclophosphamide; Drug Dosage Calculations; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Neoplasm, Residual; Recurrence; Research Design; Time Factors; Treatment Outcome; United Kingdom; Vidarabine | 2016 |
A phase I-II trial of fludarabine, bendamustine and rituximab (FBR) in previously treated patients with CLL.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Female; Follow-Up Studies; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Neoplasm Staging; Prognosis; Rituximab; Survival Rate; Vidarabine | 2017 |
Randomized phase 2 study of otlertuzumab and bendamustine versus bendamustine in patients with relapsed chronic lymphocytic leukaemia.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Disease-Free Survival; Drug Administration Schedule; Female; Fever; Humans; Immunoglobulin G; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Neutropenia; Recombinant Fusion Proteins; Recurrence; Remission Induction; Salvage Therapy | 2017 |
A multicenter, single-arm, Phase II clinical trial of bendamustine monotherapy in patients with chronic lymphocytic leukemia in Japan.
Topics: Aged; Antineoplastic Agents, Alkylating; Bendamustine Hydrochloride; Female; Humans; Infusions, Intravenous; Japan; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Treatment Outcome | 2017 |
Phase III randomized study of bendamustine compared with chlorambucil in previously untreated patients with chronic lymphocytic leukemia.
Topics: Adult; Aged; Antineoplastic Agents; Bendamustine Hydrochloride; Chlorambucil; Disease-Free Survival; Female; Fever; Follow-Up Studies; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Nausea; Neutropenia; Nitrogen Mustard Compounds; Thrombocytopenia; Time Factors; Treatment Outcome | 2009 |
Efficacy of bendamustine in rituximab-refractory indolent B-cell non-Hodgkin lymphoma: review of a pivotal trial.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Bendamustine Hydrochloride; Disease-Free Survival; Drug Therapy, Combination; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, B-Cell; Male; Middle Aged; Nitrogen Mustard Compounds; Rituximab; Treatment Outcome | 2011 |
Bendamustine combined with rituximab in patients with relapsed and/or refractory chronic lymphocytic leukemia: a multicenter phase II trial of the German Chronic Lymphocytic Leukemia Study Group.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Drug Resistance, Neoplasm; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Intention to Treat Analysis; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Neoplasm, Residual; Nitrogen Mustard Compounds; Prospective Studies; Recurrence; Rituximab; Survival Analysis; Vidarabine | 2011 |
Bendamustine plus mitoxantrone for relapsed/refractory chronic lymphocytic leukaemia (CLL): results of a multicentre phase II study of the German CLL Study Group (GCLLSG).
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Drug Administration Schedule; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Mitoxantrone; Nitrogen Mustard Compounds; Recurrence; Treatment Outcome | 2012 |
Bendamustine compared with chlorambucil in previously untreated patients with chronic lymphocytic leukaemia: updated results of a randomized phase III trial.
Topics: Antineoplastic Agents, Alkylating; Bendamustine Hydrochloride; Chlorambucil; Disease-Free Survival; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Nitrogen Mustard Compounds | 2012 |
Bendamustine in combination with rituximab for previously untreated patients with chronic lymphocytic leukemia: a multicenter phase II trial of the German Chronic Lymphocytic Leukemia Study Group.
Topics: Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Disease-Free Survival; Drug Administration Schedule; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Nitrogen Mustard Compounds; Rituximab | 2012 |
Bendamustine compared to fludarabine as second-line treatment in chronic lymphocytic leukemia.
Topics: Adult; Aged; Aged, 80 and over; Algorithms; Antineoplastic Agents; Bendamustine Hydrochloride; Chemotherapy, Adjuvant; Female; Germany; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Nitrogen Mustard Compounds; Survival Analysis; Treatment Outcome; Vidarabine | 2013 |
High rates of long-lasting remissions after 5-day bendamustine chemotherapy cycles in pre-treated low-grade non-Hodgkin's-lymphomas.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Bendamustine Hydrochloride; Female; Hematologic Diseases; Humans; Infusions, Intravenous; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphocytes; Lymphoma, Follicular; Lymphoma, Non-Hodgkin; Lymphopenia; Male; Maximum Tolerated Dose; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Nitrogen Mustard Compounds; Prognosis; Remission Induction; Salvage Therapy; Survival Rate | 2002 |
Bendamustine plus mitoxantrone--a new effective treatment for advanced chronic lymphocytic leukaemia: results of a phase I/II study.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Dose-Response Relationship, Drug; Female; Hematologic Diseases; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Mitoxantrone; Nitrogen Mustard Compounds; Opportunistic Infections; Remission Induction; Survival Analysis | 2004 |
Bendamustine/Mitoxantrone/Rituximab (BMR): a very effective, well tolerated outpatient chemoimmunotherapy for relapsed and refractory CD20-positive indolent malignancies. Final results of a pilot study.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antigens, CD20; Bendamustine Hydrochloride; Disease Progression; Drug Therapy, Combination; Female; Humans; Immunotherapy; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Mitoxantrone; Nitrogen Mustard Compounds; Outpatients; Pilot Projects; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Recurrence; Rituximab; Survival Rate; Time Factors; World Health Organization | 2004 |
Bendamustine, vincristine and prednisone (BOP) versus cyclophosphamide, vincristine and prednisone (COP) in advanced indolent non-Hodgkin's lymphoma and mantle cell lymphoma: results of a randomised phase III trial (OSHO# 19).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Cyclophosphamide; Disease-Free Survival; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Follicular; Lymphoma, Mantle-Cell; Lymphoma, Non-Hodgkin; Male; Middle Aged; Nitrogen Mustard Compounds; Prednisone; Survival Analysis; Treatment Outcome; Vincristine | 2006 |
Efficacy of bendamustine in patients with relapsed or refractory chronic lymphocytic leukemia: results of a phase I/II study of the German CLL Study Group.
Topics: Aged; Aged, 80 and over; Bendamustine Hydrochloride; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Germany; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Neoplasm Recurrence, Local; Nitrogen Mustard Compounds; Survival Analysis | 2005 |
Phase-I/II study to evaluate dose limiting toxicity, maximum tolerated dose, and tolerability of bendamustine HCl in pre-treated patients with B-chronic lymphocytic leukaemia (Binet stages B and C) requiring therapy.
Topics: Aged; Antineoplastic Agents; Bendamustine Hydrochloride; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Neoplasm Staging; Nitrogen Mustard Compounds; Time Factors; Treatment Outcome | 2006 |
Bendamustine monotherapy in advanced and refractory chronic lymphocytic leukemia.
Topics: Adult; Aged; Aged, 80 and over; Alkylating Agents; Antineoplastic Agents, Alkylating; Bendamustine Hydrochloride; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Cyclophosphamide; Female; Humans; Immunophenotyping; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Nitrogen Mustard Compounds; Random Allocation; Time Factors | 2001 |
Bendamustine mitoxantrone and rituximab (BMR): a new effective regimen for refractory or relapsed indolent lymphomas.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Disease-Free Survival; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, B-Cell; Middle Aged; Mitoxantrone; Nitrogen Mustard Compounds; Remission Induction; Rituximab; Salvage Therapy | 2002 |
136 other study(ies) available for bendamustine hydrochloride and Leukemia, Lymphocytic, Chronic, B-Cell
| Article | Year |
|---|---|
Reversible Cardiomyopathy after Rituximab Treatment in a Chronic Lymphocytic Leukemia Patient.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Cardiomyopathies; Cough; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Rituximab | 2022 |
Correspondence in reference to the previously published manuscript: Reduction of cycles of bendamustine plus rituximab therapy in the cases with good response for indolent B-cell lymphomas.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, B-Cell; Lymphoma, Non-Hodgkin; Rituximab | 2023 |
Rate of major bleeding with ibrutinib versus bendamustine-rituximab in chronic lymphocytic leukemia: A population-based cohort study.
Topics: Adenine; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Cohort Studies; Hemorrhage; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Piperidines; Rituximab | 2022 |
Sequential treatment with bendamustine, obinutuzumab (GA101) and Ibrutinib in chronic lymphocytic leukemia (CLL): final results of the CLL2-BIG trial.
Topics: Adenine; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Clinical Trials as Topic; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Piperidines | 2022 |
Predictive role of NKCD56bright cells in monitoring the progression of chronic lymphocytic leukemia during treatment.
Topics: Antibodies, Monoclonal; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Cyclophosphamide; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-bcl-2; Rituximab; Tumor Microenvironment | 2022 |
Cost-utility analysis of venetoclax in combination with obinutuzumab as first-line treatment of chronic lymphocytic leukaemia in Spain.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Bridged Bicyclo Compounds, Heterocyclic; Chlorambucil; Cost-Benefit Analysis; Cyclophosphamide; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Quality of Life; Rituximab; Spain; Sulfonamides | 2022 |
Efficacy and safety of obinutuzumab combined with fludarabine and cyclophosphamide (FCG) or bendamustine (BG) in relapsed or refractory CLL patients followed by maintenance therapy with obinutuzumab for responding patients.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Cyclophosphamide; Humans; Leukemia, Lymphocytic, Chronic, B-Cell | 2023 |
Real-world outcomes upon second-line treatment in patients with chronic lymphocytic leukaemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Chlorambucil; Cyclophosphamide; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Retrospective Studies; Rituximab | 2023 |
[Efficacy and safety of BTK inhibitor combined with bendamustine and rituximab in the first-line treatment of chronic lymphocytic leukemia/small lymphocytic lymphoma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, B-Cell; Protein Kinase Inhibitors; Rituximab; Treatment Outcome | 2023 |
Geriatric assessment measures are predictive of outcomes in chronic lymphocytic leukemia.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Geriatric Assessment; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Progression-Free Survival; Rituximab | 2023 |
Cost-Effectiveness of Ibrutinib as First-line Treatment for Older Patients With Chronic Lymphocytic Leukemia in Iran.
Topics: Aged; Bendamustine Hydrochloride; Cost-Benefit Analysis; Humans; Iran; Leukemia, Lymphocytic, Chronic, B-Cell; Rituximab | 2023 |
HLH and TET2 Mutation Presenting after First Cycle of CLL Treatment.
Topics: Bendamustine Hydrochloride; Dioxygenases; DNA-Binding Proteins; Granulocyte Colony-Stimulating Factor; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphohistiocytosis, Hemophagocytic; Rituximab | 2023 |
Ibrutinib versus bendamustine plus rituximab for first-line treatment of 65 or older patients with untreated chronic lymphocytic leukemia without del(17p)/TP53 mutation in China: a lifetime economic research study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Cost-Benefit Analysis; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Mutation; Rituximab; Tumor Suppressor Protein p53 | 2023 |
IGHV mutational status and outcome for patients with chronic lymphocytic leukemia upon treatment: a Danish nationwide population-based study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Denmark; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Rituximab; Treatment Outcome | 2020 |
Safety and Efficacy of Bendamustine Monotherapy in the First-Line Treatment of Patients with Chronic Lymphocytic Leukemia: Polish Lymphoma Research Group Real-Life Analysis.
Topics: Aged; Aged, 80 and over; Bendamustine Hydrochloride; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Neutropenia; Retrospective Studies; Survival Rate; Thrombocytopenia; Treatment Outcome | 2019 |
Influence of obesity and gender on treatment outcomes in patients with chronic lymphocytic leukemia (CLL) undergoing rituximab-based chemoimmunotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Clinical Trials, Phase III as Topic; Female; Follow-Up Studies; Humans; Immunotherapy; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Obesity; Prognosis; Prospective Studies; Rituximab; Sex Factors; Survival Rate; Vidarabine | 2020 |
Single-agent ibrutinib in RESONATE-2™ and RESONATE™ versus treatments in the real-world PHEDRA databases for patients with chronic lymphocytic leukemia.
Topics: Adenine; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Cyclophosphamide; Databases, Factual; Disease-Free Survival; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Piperidines; Pyrazoles; Pyrimidines; Rituximab; Survival Rate; Vidarabine | 2019 |
Sensitivity of chronic lymphocytic leukemia cells to chemotherapeutic drugs ex vivo depends on expression status of cell surface receptors.
Topics: Antigens, CD; Antineoplastic Agents; B-Lymphocytes; Bendamustine Hydrochloride; Cell Line, Tumor; Cell Survival; Cyclophosphamide; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Leukocytes, Mononuclear; Receptors, Cell Surface; Vidarabine | 2020 |
DNA methylation of chronic lymphocytic leukemia with differential response to chemotherapy.
Topics: Bendamustine Hydrochloride; DNA Methylation; Drug Resistance, Neoplasm; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Tumor Suppressor Protein p53; Vidarabine | 2020 |
Real-world data on efficacy and safety of obinutuzumab plus chlorambucil, rituximab plus chlorambucil, and rituximab plus bendamustine in the frontline treatment of chronic lymphocytic leukemia: The GO-CLLEAR Study by the Czech CLL Study Group.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Chlorambucil; Female; Follow-Up Studies; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Prognosis; Remission Induction; Retrospective Studies; Rituximab; Survival Rate | 2020 |
Reshaping the therapeutic landscape of chronic lymphocytic leukaemia in the era of targeted therapy.
Topics: Adaptation, Physiological; Aged; Bendamustine Hydrochloride; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Rituximab; Sweden | 2020 |
Risk-adapted bendamustine + rituximab is a tolerable treatment alternative for elderly patients with chronic lymphocytic leukaemia: a regional real-world report on 141 consecutive Swedish patients.
Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Prognosis; Retrospective Studies; Rituximab; Sweden; Treatment Outcome | 2020 |
Extended follow-up of CD4
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; CD4 Lymphocyte Count; CD4-Positive T-Lymphocytes; Female; Follow-Up Studies; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Recovery of Function; Rituximab | 2021 |
Efficacy of bendamustine and rituximab in unfit patients with previously untreated chronic lymphocytic leukemia. Indirect comparison with ibrutinib in a real-world setting. A GIMEMA-ERIC and US study.
Topics: Adenine; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Disease Progression; Europe; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Piperidines; Progression-Free Survival; Protein Kinase Inhibitors; Retrospective Studies; Rituximab; Time Factors; United States | 2020 |
Correspondence in reference to previously published manuscript: "Faouzi Djebbari et al. Efficacy and infection morbidity of front-line immuno-chemotherapy in follicular lymphoma. Eur J Haematol. 2020; 105: 667-671".
Topics: Bendamustine Hydrochloride; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Follicular; Morbidity | 2021 |
Epidemiology, longitudinal treatment patterns and outcomes of chronic lymphocytic leukemia in Israel.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Cyclophosphamide; Humans; Israel; Leukemia, Lymphocytic, Chronic, B-Cell; Rituximab; Vidarabine | 2021 |
Outcomes of primary and secondary prophylaxis of chemotherapy-induced and febrile neutropenia in bendamustine plus rituximab regimens in patients with lymphoma and chronic lymphocytic leukemia: real-world, single-center experience.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Febrile Neutropenia; Female; Humans; Incidence; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Non-Hodgkin; Male; Middle Aged; Retrospective Studies; Rituximab; Treatment Outcome | 2021 |
Real-world healthcare resource utilization and costs in patients with chronic lymphocytic leukemia: differences between patients treated with first-line ibrutinib or bendamustine + rituximab.
Topics: Adenine; Bendamustine Hydrochloride; Health Care Costs; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Patient Acceptance of Health Care; Piperidines; Retrospective Studies; Rituximab | 2021 |
Risk of new malignancies among patients with CLL treated with chemotherapy: results of a Danish population-based study.
Topics: Aged; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Bendamustine Hydrochloride; Chlorambucil; Cohort Studies; Denmark; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Myelodysplastic Syndromes; Neoplasms, Second Primary; Registries; Risk Assessment; Survival Analysis; Vidarabine | 2021 |
Chronic Lymphocytic Leukemia Presenting as Scleral Nodule.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Biomarkers, Tumor; Cytarabine; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Rituximab; Scleral Diseases | 2021 |
Effectiveness of ibrutinib as first-line therapy for chronic lymphocytic leukemia patients and indirect comparison with rituximab-bendamustine: Results of study on 486 cases outside clinical trials.
Topics: Adenine; Aged; Bendamustine Hydrochloride; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Piperidines; Progression-Free Survival; Rituximab | 2021 |
Long-term safety experience with bendamustine for injection in a real-world setting.
Topics: Adverse Drug Reaction Reporting Systems; Antineoplastic Agents, Alkylating; Bendamustine Hydrochloride; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, B-Cell; Pharmacovigilance; Product Surveillance, Postmarketing | 2017 |
Impact of novel agents on patient-relevant outcomes in patients with previously untreated chronic lymphocytic leukemia who are not eligible for fludarabine-based therapy.
Topics: Adenine; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Chlorambucil; Health Resources; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Models, Econometric; Piperidines; Pyrazoles; Pyrimidines; Quality-Adjusted Life Years; Rituximab; Survival Analysis | 2017 |
Bendamustine plus rituximab in chronic lymphocytic leukemia: is there life in the old dog yet?
Topics: Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Chlorambucil; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Rituximab | 2018 |
Validation of a biological score to predict response in chronic lymphocytic leukemia patients treated front-line with bendamustine and rituximab.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Biomarkers, Tumor; Cohort Studies; Female; Follow-Up Studies; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Neoplasm Recurrence, Local; Prognosis; Rituximab; Severity of Illness Index; Survival Rate | 2018 |
Efficacy of bendamustine and rituximab as first salvage treatment in chronic lymphocytic leukemia and indirect comparison with ibrutinib: a GIMEMA, ERIC and UK CLL FORUM study.
Topics: Adenine; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Biomarkers, Tumor; Humans; Italy; Leukemia, Lymphocytic, Chronic, B-Cell; Middle Aged; Piperidines; Prognosis; Pyrazoles; Pyrimidines; Retreatment; Rituximab; Salvage Therapy; Survival Analysis; Treatment Outcome; United Kingdom | 2018 |
Presentation and management of the delayed type of hypersensitivity reaction with bendamustine.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Desensitization, Immunologic; Drug Hypersensitivity; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Rituximab | 2018 |
Still a role for second-line chemoimmunotherapy in chronic lymphocytic leukemia?
Topics: Adenine; Bendamustine Hydrochloride; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Piperidines; Pyrazoles; Pyrimidines; Rituximab; Salvage Therapy; United Kingdom | 2018 |
Early Direct Antiglobulin Test Negativity after Bendamustine and Rituximab Treatment in Chronic Lymphocytic Leukemia: Two Cases
Topics: Aged; Anemia, Hemolytic, Autoimmune; Antineoplastic Agents; Bendamustine Hydrochloride; Coombs Test; False Positive Reactions; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Rituximab | 2018 |
Venetoclax in chronic lymphocytic leukaemia: a possible cure?
Topics: Antibodies, Monoclonal, Humanized; Bendamustine Hydrochloride; Bridged Bicyclo Compounds, Heterocyclic; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Neoplasm Recurrence, Local; Sulfonamides | 2018 |
Bendamustine alone or with rituximab modifies expression of apoptosis-regulating genes and proteins of CLL cells, depending on IGVH mutational status.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Apoptosis Regulatory Proteins; bcl-2-Associated X Protein; Bendamustine Hydrochloride; Female; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Immunoglobulin Heavy Chains; Immunoglobulin Variable Region; Leukemia, Lymphocytic, Chronic, B-Cell; Leukocytes, Mononuclear; Male; Middle Aged; Mutation; Primary Cell Culture; Proto-Oncogene Proteins; Rituximab; Tumor Cells, Cultured; Young Adult | 2019 |
Real-world testing and treatment patterns in chronic lymphocytic leukemia: A SEER patterns of care analysis.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Bendamustine Hydrochloride; Diagnostic Techniques and Procedures; DNA Mutational Analysis; Female; Humans; Immunoglobulin Variable Region; In Situ Hybridization, Fluorescence; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Rituximab; SEER Program; Sentinel Lymph Node Biopsy | 2019 |
Selective BTK inhibition improves bendamustine therapy response and normalizes immune effector functions in chronic lymphocytic leukemia.
Topics: Acrylamides; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Animals; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Bone Marrow; Disease Models, Animal; Drug Screening Assays, Antitumor; Drug Synergism; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Mice; Mice, Inbred C57BL; Mice, Transgenic; Middle Aged; Primary Cell Culture; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Pyrimidines; Tumor Cells, Cultured | 2019 |
Bendamustine and Rituximab Treatment, Chronic Lymphocytic Leukemia, Direct Antiglobulin Test, and False Negatives
Topics: Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Coombs Test; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Rituximab | 2019 |
Establishment of a comprehensive chronic lymphocytic leukemia clinic at a tertiary referral center in India.
Topics: Antineoplastic Agents; Bendamustine Hydrochloride; Chlorambucil; Disease Management; Humans; India; Leukemia, Lymphocytic, Chronic, B-Cell; Middle Aged; Quality of Life; Rituximab; Tertiary Care Centers; Treatment Outcome | 2018 |
CLL2-BIG: sequential treatment with bendamustine, ibrutinib and obinutuzumab (GA101) in chronic lymphocytic leukemia.
Topics: Adenine; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Biomarkers; Bone Marrow; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Piperidines; Pyrazoles; Pyrimidines; Remission Induction; Survival Analysis; Tomography, X-Ray Computed; Treatment Outcome | 2019 |
Durable remissions with obinutuzumab-based chemoimmunotherapy: long-term follow-up of the phase 1b GALTON trial in CLL.
Topics: Antibodies, Monoclonal, Humanized; Bendamustine Hydrochloride; Cyclophosphamide; Follow-Up Studies; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Vidarabine | 2019 |
Prospective observational study in comorbid patients with chronic lymphocytic leukemia receiving first-line bendamustine with rituximab.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Comorbidity; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Neoadjuvant Therapy; Rituximab; Treatment Outcome | 2019 |
Marginal zone lymphoma-associated antiphospholipid antibodies successfully treated with bendamustine rituximab.
Topics: Antibodies, Antiphospholipid; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Immunological; Antiphospholipid Syndrome; Bendamustine Hydrochloride; Diagnosis, Differential; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, B-Cell, Marginal Zone; Male; Middle Aged; Rare Diseases; Rituximab; Treatment Outcome | 2019 |
Rituximab/Bendamustine treatment of chronic lymphatic leukemia leads to sustained remission of antiphospholipid antibodies.
Topics: Antineoplastic Combined Chemotherapy Protocols; Antiphospholipid Syndrome; Bendamustine Hydrochloride; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Middle Aged; Rituximab | 2019 |
Impact of gene mutations and chromosomal aberrations on progression-free survival in chronic lymphocytic leukemia patients treated with front-line chemoimmunotherapy: Clinical practice experience.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Biomarkers, Tumor; Chromosome Aberrations; Chromosomes, Human, Pair 11; Cohort Studies; Cyclophosphamide; Female; Follow-Up Studies; Humans; Immunoglobulin Heavy Chains; Immunoglobulin Variable Region; Immunotherapy; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Mutation; Prognosis; Rituximab; Survival Rate; Vidarabine | 2019 |
Acquired von Willebrand syndrome in a patient with small lymphocytic lymphoma and Sjögren's syndrome: which associated condition should be prioritized?
Topics: Aged; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Immunological; Bendamustine Hydrochloride; Female; Hemorrhage; Humans; Immunoglobulins; Leukemia, Lymphocytic, Chronic, B-Cell; Rituximab; Sjogren's Syndrome; von Willebrand Diseases | 2019 |
Prognostic and Predictive Effect of IGHV Mutational Status and Load in Chronic Lymphocytic Leukemia: Focus on FCR and BR Treatments.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Cyclophosphamide; Female; Humans; Immunoglobulin Heavy Chains; Immunoglobulin Variable Region; Kaplan-Meier Estimate; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Multivariate Analysis; Mutation; Predictive Value of Tests; Prognosis; Retrospective Studies; Rituximab; Treatment Outcome; Vidarabine | 2019 |
[Current and future indications for bendamustine: chronic lymphocytic leukemia, indolent lymphoma, mantle cell lymphoma and diffuse large B-cell lymphomas].
Topics: Animals; Antineoplastic Agents, Alkylating; Bendamustine Hydrochloride; Dose-Response Relationship, Drug; Forecasting; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma; Nitrogen Mustard Compounds | 2013 |
The combination of rituximab, bendamustine, and cytarabine for heavily pretreated relapsed/refractory cytogenetically high-risk patients with chronic lymphocytic leukemia.
Topics: Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Chromosome Aberrations; Chromosomes, Human, Pair 11; Chromosomes, Human, Pair 17; Cytarabine; Cytogenetic Analysis; Drug Administration Schedule; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Neoplasm Staging; Nitrogen Mustard Compounds; Pilot Projects; Recurrence; Risk; Rituximab; Sequence Deletion; Survival Analysis | 2013 |
The use of rituximab and bendamustine in treating chronic lymphocytic leukaemia (CLL) in end-stage renal disease (ESRD).
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Bendamustine Hydrochloride; Diabetes Mellitus, Type 2; Female; Humans; Kidney; Kidney Failure, Chronic; Leukemia, Lymphocytic, Chronic, B-Cell; Middle Aged; Nitrogen Mustard Compounds; Peritoneal Dialysis; Rituximab | 2013 |
Bendamustine in chronic lymphocytic leukemia: outcome according to different clinical and biological prognostic factors in the everyday clinical practice.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Female; Follow-Up Studies; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Neoplasm Staging; Neutropenia; Nitrogen Mustard Compounds; Prognosis; Reproducibility of Results; Retrospective Studies; Rituximab; Survival Analysis | 2013 |
Single centre study of using bendamustine in the treatment of B-cell malignancies.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Bendamustine Hydrochloride; Female; Follow-Up Studies; Humans; Infusions, Intravenous; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, B-Cell; Male; Middle Aged; Nitrogen Mustard Compounds; Remission Induction; Retrospective Studies; Treatment Outcome | 2013 |
Therapy-related acute myeloid leukemia in a patient with chronic lymphocytic leukemia treated with rituximab-bendamustine.
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents, Alkylating; Bendamustine Hydrochloride; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Myeloid, Acute; Male; Middle Aged; Nitrogen Mustard Compounds; Rituximab | 2014 |
Short communication: bendamustine-related hemolytic anemia in chronic lymphocytic leukemia.
Topics: Aged; Anemia, Hemolytic; Antineoplastic Agents, Alkylating; Bendamustine Hydrochloride; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Nitrogen Mustard Compounds; Risk Factors; T-Lymphocytes | 2013 |
The safety of bendamustine in patients with chronic lymphocytic leukemia or non-Hodgkin lymphoma and concomitant renal impairment: a retrospective electronic medical record database analysis.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Bendamustine Hydrochloride; Creatinine; Databases, Factual; Female; Follow-Up Studies; Glomerular Filtration Rate; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Non-Hodgkin; Male; Middle Aged; Nitrogen Mustard Compounds; Renal Insufficiency; Retrospective Studies; Treatment Outcome | 2014 |
Akt inhibitor MK2206 selectively targets CLL B-cell receptor induced cytokines, mobilizes lymphocytes and synergizes with bendamustine to induce CLL apoptosis.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Bendamustine Hydrochloride; Cytokines; Drug Synergism; Heterocyclic Compounds, 3-Ring; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphocytes; Nitrogen Mustard Compounds; Proto-Oncogene Proteins c-akt | 2014 |
Bendamustine plus alemtuzumab is safe and feasible treatment for fludarabine refractory chronic lymphocytic leukaemia (CLL).
Topics: Alemtuzumab; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Nitrogen Mustard Compounds; Treatment Outcome; Vidarabine | 2014 |
Poly(ADP-ribose) polymerase inhibitor CEP-8983 synergizes with bendamustine in chronic lymphocytic leukemia cells in vitro.
Topics: Antineoplastic Agents, Alkylating; B-Lymphocytes; Bendamustine Hydrochloride; BRCA1 Protein; Carbazoles; DNA Damage; DNA Methylation; DNA Repair; DNA Repair Enzymes; DNA, Neoplasm; Drug Synergism; Enzyme Inhibitors; Gene Expression Regulation, Leukemic; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Nitrogen Mustard Compounds; Phthalimides; Poly(ADP-ribose) Polymerase Inhibitors; Poly(ADP-ribose) Polymerases; Promoter Regions, Genetic; Sequence Analysis, DNA; Signal Transduction | 2014 |
Bendamustine as monotherapy and in combination regimens for the treatment of chronic lymphocytic leukemia and non-hodgkin lymphoma: a retrospective analysis.
Topics: Aged; Aged, 80 and over; Anemia; Antibodies, Monoclonal, Murine-Derived; Bendamustine Hydrochloride; Disease-Free Survival; Drug Therapy, Combination; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Non-Hodgkin; Male; Middle Aged; Neutropenia; Nitrogen Mustard Compounds; Retrospective Studies; Rituximab; Thrombocytopenia | 2013 |
Targeting the proliferative and chemoresistant compartment in chronic lymphocytic leukemia by inhibiting survivin protein.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Apoptosis; B-Lymphocytes; Bendamustine Hydrochloride; Bone Marrow Cells; CD40 Antigens; Cell Cycle; Cell Proliferation; Coculture Techniques; Drug Resistance, Neoplasm; Female; Gene Deletion; Humans; Imidazoles; Inhibitor of Apoptosis Proteins; Leukemia, Lymphocytic, Chronic, B-Cell; Leukocytes, Mononuclear; Male; Middle Aged; Naphthoquinones; Nitrogen Mustard Compounds; Stromal Cells; Survivin; Toll-Like Receptor 9; Vidarabine | 2014 |
Routine treatment of patients with chronic lymphocytic leukaemia by office-based haematologists in Germany-data from the Prospective Tumour Registry Lymphatic Neoplasms.
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Chlorambucil; Cyclophosphamide; Female; Germany; Hematology; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Nitrogen Mustard Compounds; Office Visits; Prednisone; Prospective Studies; Registries; Rituximab; Vidarabine | 2015 |
Evaluation of bendamustine in combination with fludarabine in primary chronic lymphocytic leukemia cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Bendamustine Hydrochloride; Bone Marrow Cells; Cells, Cultured; Drug Administration Schedule; Drug Evaluation, Preclinical; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Nitrogen Mustard Compounds; Primary Cell Culture; Stromal Cells; Time Factors; Vidarabine | 2014 |
Simultaneous determination of bendamustine and its active metabolite, gamma-hydroxy-bendamustine in human plasma and urine using HPLC-fluorescence detector: application to a pharmacokinetic study in Chinese cancer patients.
Topics: Aged; Antineoplastic Agents, Alkylating; Bendamustine Hydrochloride; China; Chromatography, High Pressure Liquid; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Linear Models; Lymphoma, B-Cell; Male; Middle Aged; Nitrogen Mustard Compounds; Reproducibility of Results; Sensitivity and Specificity | 2014 |
Successful treatment of refractory Guillain-Barré syndrome with alemtuzumab in a patient with chronic lymphocytic leukemia.
Topics: Aged; Alemtuzumab; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antigens, CD; Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Autoantibodies; Autoantigens; Bendamustine Hydrochloride; CD52 Antigen; Combined Modality Therapy; Consciousness Disorders; Gangliosides; Glycoproteins; Guillain-Barre Syndrome; Herpes Zoster; Herpesvirus 3, Human; Humans; Immunoglobulins, Intravenous; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Methylprednisolone; Miller Fisher Syndrome; Nitrogen Mustard Compounds; Plasmapheresis; Remission Induction; Rituximab; Virus Activation | 2014 |
Recurrent and partially reversible cardiomyopathy occurring during treatment with bendamustine and rituximab.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Cardiomyopathies; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphocyte Count; Male; Rituximab | 2015 |
Changes in the diagnosis and treatment of patients with low grade lymphoma in Germany: years 2006-2009.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Bendamustine Hydrochloride; Female; Germany; Health Care Surveys; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Non-Hodgkin; Male; Middle Aged; Retrospective Studies; Rituximab; Young Adult | 2015 |
Lymphocyte recovery is impaired in patients with chronic lymphocytic leukemia and indolent non-Hodgkin lymphomas treated with bendamustine plus rituximab.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; CD4-Positive T-Lymphocytes; Female; Follow-Up Studies; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphocytes; Lymphoma, Non-Hodgkin; Male; Middle Aged; Nitrogen Mustard Compounds; Rituximab; Treatment Outcome | 2014 |
Bendamustine and subcutaneous alemtuzumab combination is an effective treatment in relapsed/refractory chronic lymphocytic leukemia patients.
Topics: Adolescent; Adult; Aged; Alemtuzumab; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Alkylating; Bendamustine Hydrochloride; Drug Administration Schedule; Drug Combinations; Female; Humans; Injections, Intravenous; Injections, Subcutaneous; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Nitrogen Mustard Compounds; Recurrence; Survival Analysis; Treatment Outcome | 2014 |
Appropriate use of bendamustine in first-line therapy of chronic lymphocytic leukemia. Recommendations from SIE, SIES, GITMO Group.
Topics: Antineoplastic Agents, Alkylating; Bendamustine Hydrochloride; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Nitrogen Mustard Compounds | 2014 |
Bendamustine in CLL: How quickly will today's consensus become tomorrow's memory?
Topics: Antineoplastic Agents, Alkylating; Bendamustine Hydrochloride; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Nitrogen Mustard Compounds | 2014 |
Hypoxia-induced p38 MAPK activation reduces Mcl-1 expression and facilitates sensitivity towards BH3 mimetics in chronic lymphocytic leukemia.
Topics: Antineoplastic Agents; B-Lymphocytes; bcl-X Protein; Bendamustine Hydrochloride; Biphenyl Compounds; Bridged Bicyclo Compounds, Heterocyclic; CD40 Ligand; Cell Hypoxia; Cells, Cultured; Drug Resistance, Neoplasm; Enzyme Activation; Gene Expression Regulation, Leukemic; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Myeloid Cell Leukemia Sequence 1 Protein; Nitrogen Mustard Compounds; Nitrophenols; Oxygen; p38 Mitogen-Activated Protein Kinases; Piperazines; Proto-Oncogene Proteins c-bcl-2; Signal Transduction; Sulfonamides; Vidarabine | 2015 |
Huge kidneys in a patient with chronic lymphocytic leukaemia.
Topics: Acute Kidney Injury; Antineoplastic Agents, Alkylating; Bendamustine Hydrochloride; Biopsy; Humans; Kidney; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemic Infiltration; Male; Middle Aged; Nitrogen Mustard Compounds; Remission Induction; Renal Dialysis; Tomography, X-Ray Computed | 2015 |
Bendamustine and rituximab combination in the management of chronic lymphocytic leukemia-associated autoimmune hemolytic anemia: a multicentric retrospective study of the French CLL intergroup (GCFLLC/MW and GOELAMS).
Topics: Aged; Aged, 80 and over; Anemia, Hemolytic, Autoimmune; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Bendamustine Hydrochloride; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Nitrogen Mustard Compounds; Retrospective Studies; Rituximab; Survival Analysis | 2015 |
Renal human organic anion transporter 3 increases the susceptibility of lymphoma cells to bendamustine uptake.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Bendamustine Hydrochloride; Cell Proliferation; Chlorambucil; Dose-Response Relationship, Drug; Estrone; HEK293 Cells; Humans; Jurkat Cells; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, T-Cell; Melphalan; Nitrogen Mustard Compounds; Organic Anion Transport Protein 1; Organic Anion Transporters, Sodium-Independent; p-Aminohippuric Acid; Transfection; Tumor Cells, Cultured | 2015 |
Cytotoxic and apoptosis-inducing effects of bendamustine used alone and in combination with rituximab on chronic lymphocytic leukemia cells in vitro.
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Bendamustine Hydrochloride; Caspases; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Leukocytes, Mononuclear; Membrane Potential, Mitochondrial; Nitrogen Mustard Compounds; Rituximab; Tumor Cells, Cultured | 2014 |
Hypersensitivity reactions and drug fever by bendamustine: a case report of three patients.
Topics: Antineoplastic Agents, Alkylating; Bendamustine Hydrochloride; Drug Hypersensitivity; Female; Fever; Humans; Immunoglobulin E; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Skin; Skin Tests | 2015 |
Human organic cation transporter 1 (hOCT1) as a mediator of bendamustine uptake and cytotoxicity in chronic lymphocytic leukemia (CLL) cells.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Bendamustine Hydrochloride; Cell Line, Tumor; Cell Survival; Cohort Studies; DNA, Complementary; Equilibrative Nucleoside Transporter 1; Exome; Female; Genotype; HEK293 Cells; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Membrane Transport Proteins; Middle Aged; Organic Anion Transporters; Organic Cation Transport Proteins; Organic Cation Transporter 1; Polymorphism, Genetic | 2015 |
Highlights in the treatment of chronic lymphocytic leukemia from the 2014 meeting of the American Society of Hematology.
Topics: Adenine; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bendamustine Hydrochloride; Disease-Free Survival; Drug Discovery; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Molecular Targeted Therapy; Piperidines; Protein Kinase Inhibitors; Purines; Pyrazoles; Pyrimidines; Quinazolinones; Rituximab; San Francisco; Societies, Medical | 2015 |
Pharmacological and Protein Profiling Suggests Venetoclax (ABT-199) as Optimal Partner with Ibrutinib in Chronic Lymphocytic Leukemia.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Aged; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; B-Cell Activating Factor; bcl-X Protein; Bendamustine Hydrochloride; Biphenyl Compounds; Bridged Bicyclo Compounds, Heterocyclic; Female; Gene Expression Regulation, Leukemic; Humans; Isoquinolines; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Neoplastic Cells, Circulating; Nitrophenols; Piperazines; Piperidines; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-bcl-2; Purines; Pyrazoles; Pyrimidines; Sulfonamides | 2015 |
Combo Therapy Effective for Relapsed CLL.
Topics: Adenine; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Clinical Trials, Phase III as Topic; Disease-Free Survival; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Piperidines; Pyrazoles; Pyrimidines; Rituximab; Standard of Care; Treatment Outcome | 2015 |
Targeting neddylation induces DNA damage and checkpoint activation and sensitizes chronic lymphocytic leukemia B cells to alkylating agents.
Topics: Alkylating Agents; Apoptosis; B-Lymphocytes; Bendamustine Hydrochloride; CD40 Antigens; CD40 Ligand; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Cyclopentanes; DNA Damage; Gene Expression Regulation, Neoplastic; Humans; Interleukins; Leukemia, Lymphocytic, Chronic, B-Cell; NEDD8 Protein; NF-kappa B; Pyrimidines; Ubiquitin-Activating Enzymes; Ubiquitins | 2015 |
Routine Use of Bendamustine in Patients with Chronic Lymphocytic Leukemia: An Observational Study.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Cohort Studies; Disease-Free Survival; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Multivariate Analysis; Rituximab; Treatment Outcome | 2015 |
Bendamustine in combination with rituximab for elderly patients with previously untreated B-cell chronic lymphocytic leukemia: A retrospective analysis of real-life practice in Italian hematology departments.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Disease-Free Survival; Female; Humans; Italy; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Retrospective Studies; Rituximab | 2015 |
Leukaemia cutis after starting bendamustine: cause or coincidence?
Topics: Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Cyclophosphamide; Erythema Nodosum; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemic Infiltration; Male; Middle Aged; Rituximab; Skin; Vidarabine | 2015 |
β2 -microglobulin normalization within 6 months of ibrutinib-based treatment is associated with superior progression-free survival in patients with chronic lymphocytic leukemia.
Topics: Adenine; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; beta 2-Microglobulin; Bone Marrow; Case-Control Studies; Chromosomes, Human, Pair 11; Chromosomes, Human, Pair 17; Cohort Studies; Cyclophosphamide; Disease-Free Survival; Female; Humans; Immunoglobulin Heavy Chains; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Neoplasm, Residual; Piperidines; Prognosis; Proportional Hazards Models; Pyrazoles; Pyrimidines; Retrospective Studies; Rituximab; Treatment Outcome; Vidarabine; ZAP-70 Protein-Tyrosine Kinase | 2016 |
CD69 expression potentially predicts response to bendamustine and its modulation by ibrutinib or idelalisib enhances cytotoxic effect in chronic lymphocytic leukemia.
Topics: Adenine; Adult; Aged; Aged, 80 and over; Antigens, CD; Antigens, Differentiation, T-Lymphocyte; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Apoptosis; Bendamustine Hydrochloride; Cell Proliferation; Female; Follow-Up Studies; Humans; Lectins, C-Type; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Neoplasm Staging; Piperidines; Prognosis; Purines; Pyrazoles; Pyrimidines; Quinazolinones; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Signal Transduction; Transcriptome; Tumor Cells, Cultured | 2016 |
Autoimmune hemolytic anemia during bendamustine plus rituximab treatment in CLL patients: multicenter experience.
Topics: Aged; Anemia, Hemolytic, Autoimmune; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Female; Humans; Incidence; Italy; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Neoadjuvant Therapy; Retrospective Studies; Rituximab | 2016 |
[Minimal-change glomerulonephritis in chronic lymphocytic leukemia: A clinical case].
Topics: Antineoplastic Agents; Bendamustine Hydrochloride; Female; Glomerulonephritis; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Middle Aged; Nephrotic Syndrome; Rituximab | 2015 |
Altered treatment of chronic lymphocytic leukemia in Germany during the last decade.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Chlorambucil; Female; Germany; Health Care Surveys; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Rituximab; Treatment Outcome; Vidarabine | 2016 |
Treating the Hodgkin's Lymphoma Variant of Richter's Transformation.
Topics: Antineoplastic Agents, Alkylating; Bendamustine Hydrochloride; Hodgkin Disease; Humans; Leukemia, Lymphocytic, Chronic, B-Cell | 2016 |
Combination of bendamustine and rituximab as front-line therapy for patients with chronic lymphocytic leukaemia: multicenter, retrospective clinical practice experience with 279 cases outside of controlled clinical trials.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Retrospective Studies; Rituximab; Treatment Outcome | 2016 |
Chemotherapy of mantle cell lymphoma relapsed or refractory chronic lymphocytic leukaemia.
Topics: Adenine; Antineoplastic Agents; Bendamustine Hydrochloride; Bortezomib; Chromosomes, Human, Pair 17; Cytarabine; Humans; Lenalidomide; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Mantle-Cell; Mutation; Neoplasm Recurrence, Local; Piperidines; Pyrazoles; Pyrimidines; Rituximab; Sirolimus; Thalidomide; Tumor Suppressor Protein p53; Vidarabine | 2016 |
First reported association of chronic lymphocytic leukaemia and interstitial granulomatous dermatitis.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Dermatitis; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Rituximab; Treatment Outcome | 2016 |
A case of septic arthritis caused by a Mycoplasma salivarium strain resistant towards Ciprofloxacin and Clarithromycin in a patient with chronic lymphatic leukemia.
Topics: Aged; Anti-Bacterial Agents; Antineoplastic Agents; Arthritis, Infectious; Bendamustine Hydrochloride; Ciprofloxacin; Clarithromycin; Drug Resistance, Bacterial; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Mycoplasma Infections; Mycoplasma salivarium; Rituximab | 2016 |
Bendamustine added to allogeneic conditioning improves long-term outcomes in patients with CLL.
Topics: Adult; Aged; Bendamustine Hydrochloride; Cyclophosphamide; Disease-Free Survival; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Rituximab; Survival Rate; Transplantation Conditioning; Vidarabine | 2017 |
Cross-resistance and synergy with bendamustine in chronic lymphocytic leukemia.
Topics: Adenosine Deaminase Inhibitors; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Bendamustine Hydrochloride; Chlorambucil; Deoxyadenosines; DNA Breaks, Double-Stranded; Drug Synergism; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Pentostatin; Tumor Cells, Cultured | 2016 |
Bendamustine-induced nephrogenic diabetes insipidus
.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Diabetes Insipidus, Nephrogenic; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Rituximab | 2017 |
Idelalisib and bendamustine combination is synergistic and increases DNA damage response in chronic lymphocytic leukemia cells.
Topics: Animals; Antineoplastic Agents; Bendamustine Hydrochloride; Cell Line; Cell Survival; Cells, Cultured; DNA Damage; Dose-Response Relationship, Drug; Drug Synergism; Embryo, Mammalian; Fibroblasts; Gene Expression Regulation, Leukemic; Humans; Immunoblotting; Leukemia, Lymphocytic, Chronic, B-Cell; Mice, Knockout; Myeloid Cell Leukemia Sequence 1 Protein; Proto-Oncogene Proteins c-bcl-2; Purines; Quinazolinones; Reverse Transcriptase Polymerase Chain Reaction; Tumor Cells, Cultured | 2017 |
Bendamustine.
Topics: Antineoplastic Agents, Alkylating; Bendamustine Hydrochloride; Clinical Trials as Topic; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Molecular Structure; Nitrogen Mustard Compounds; Treatment Outcome | 2008 |
Bendamustine is effective in p53-deficient B-cell neoplasms and requires oxidative stress and caspase-independent signaling.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Apoptosis; Bendamustine Hydrochloride; Caspases; Female; Genes, p53; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Mantle-Cell; Male; Middle Aged; Mutation; Nitrogen Mustard Compounds; Oxidative Stress; Signal Transduction; Tumor Cells, Cultured | 2008 |
Bendamustine (Treanda) for CLL and NHL.
Topics: Antineoplastic Agents; Bendamustine Hydrochloride; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Non-Hodgkin; Nitrogen Mustard Compounds | 2008 |
Forodesine has high antitumor activity in chronic lymphocytic leukemia and activates p53-independent mitochondrial apoptosis by induction of p73 and BIM.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Apoptosis Regulatory Proteins; Bcl-2-Like Protein 11; Bendamustine Hydrochloride; Cyclophosphamide; DNA-Binding Proteins; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Gene Expression Regulation, Leukemic; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Membrane Proteins; Mitochondria; Nitrogen Mustard Compounds; Nuclear Proteins; Proto-Oncogene Proteins; Purine Nucleosides; Pyrimidinones; Rituximab; Tumor Cells, Cultured; Tumor Protein p73; Tumor Suppressor Protein p53; Tumor Suppressor Proteins; Vidarabine | 2009 |
Bendamustine in chronic lymphocytic leukemia: the future is combination therapy.
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Medical Oncology; Mitoxantrone; Nitrogen Mustard Compounds; Rituximab; Treatment Outcome | 2009 |
Drug essentials. An alkylating agent for CLL and NHL.
Topics: Alkylating Agents; Antineoplastic Agents; Bendamustine Hydrochloride; Fatigue; Humans; Infusions, Intravenous; Leukemia, Lymphocytic, Chronic, B-Cell; Leukopenia; Lymphoma, Non-Hodgkin; Nitrogen Mustard Compounds; Patient Education as Topic | 2009 |
Eleventh biannual report of the Cochrane Haematological Malignancies Group: Focus on Hodgkin lymphoma.
Topics: Anemia; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Bendamustine Hydrochloride; Bleomycin; Chlorambucil; Controlled Clinical Trials as Topic; Cyclophosphamide; Dacarbazine; Doxorubicin; Etoposide; Exercise; Hematinics; Hodgkin Disease; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Multicenter Studies as Topic; Myelodysplastic Syndromes; Nitrogen Mustard Compounds; Prednisone; Procarbazine; Quality of Life; Randomized Controlled Trials as Topic; Vinblastine; Vincristine | 2010 |
B-chronic lymphocytic leukemia chemoresistance involves innate and acquired leukemic side population cells.
Topics: ADP-ribosyl Cyclase 1; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Cell Separation; Coloring Agents; Drug Resistance, Neoplasm; Flow Cytometry; Humans; Interleukin-2; Leukemia, Lymphocytic, Chronic, B-Cell; Nitrogen Mustard Compounds; Phenotype; Recombinant Proteins; Rituximab; Vidarabine | 2010 |
Bendamustine/mitoxantrone/rituximab: a short remission induction chemoimmunotherapy for elderly patients with relapsed or refractory chronic lymphocytic leukemia.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Combined Modality Therapy; Drug Resistance, Neoplasm; Female; Humans; Immunotherapy; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Mitoxantrone; Nitrogen Mustard Compounds; Recurrence; Remission Induction; Retrospective Studies; Rituximab; Salvage Therapy | 2009 |
Bendamustine with or without rituximab in the treatment of relapsed chronic lymphocytic leukaemia: an Italian retrospective study.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Drug Evaluation; Drug Resistance, Neoplasm; Epidemiologic Methods; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Nitrogen Mustard Compounds; Recurrence; Rituximab; Treatment Outcome | 2011 |
Treatment of synchronous mantle cell lymphoma and small lymphocytic lymphoma with bendamustine and rituximab.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Female; Humans; In Situ Hybridization, Fluorescence; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Mantle-Cell; Nitrogen Mustard Compounds; Rituximab | 2011 |
Routine use of bendamustine and rituximab combination therapy in consecutive patients with lymphoproliferative diseases: a survey from Tyrolean hospitals.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Austria; Bendamustine Hydrochloride; Child; Cohort Studies; Dose-Response Relationship, Drug; Drug Therapy, Combination; Feasibility Studies; Female; Humans; Infant; Kaplan-Meier Estimate; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma; Lymphoproliferative Disorders; Male; Middle Aged; Nitrogen Mustard Compounds; Opportunistic Infections; Pancytopenia; Retrospective Studies; Rituximab; Treatment Outcome | 2011 |
Combination therapy with ofatumumab and bendamustine in xenograft model of chronic lymphocytic leukaemia.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antigens, CD20; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Cell Line, Tumor; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Mice; Mice, SCID; Nitrogen Mustard Compounds; Rituximab; Tumor Burden; Xenograft Model Antitumor Assays | 2012 |
Hepatitis B reactivation despite entecavir prophylaxis in a patient with chronic lymphocytic leukaemia receiving bendamustine.
Topics: Antineoplastic Agents; Antiviral Agents; Bendamustine Hydrochloride; Chemoprevention; DNA, Viral; Guanine; Hepatitis B; Hepatitis B virus; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Nitrogen Mustard Compounds; Virus Activation | 2012 |
Clinical experience of bendamustine treatment for non-Hodgkin lymphoma and chronic lymphocytic leukemia in Spain.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Bendamustine Hydrochloride; Compassionate Use Trials; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Non-Hodgkin; Male; Middle Aged; Neoplasm Invasiveness; Nitrogen Mustard Compounds; Retrospective Studies; Spain; Treatment Outcome | 2012 |
Preliminary experience with the use of bendamustine: a peculiar skin rash as the commonest side effect.
Topics: Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents, Alkylating; Bendamustine Hydrochloride; Drug Therapy, Combination; Exanthema; Female; Humans; India; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Follicular; Male; Middle Aged; Nitrogen Mustard Compounds; Prednisolone; Retrospective Studies; Rituximab; Vincristine | 2011 |
Bendamustine: inadequate or outdated data.
Topics: Antineoplastic Agents, Alkylating; Bendamustine Hydrochloride; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Non-Hodgkin; Multiple Myeloma; Nitrogen Mustard Compounds; Randomized Controlled Trials as Topic | 2012 |
Making advances in first-line chronic lymphocytic leukemia treatment.
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Nitrogen Mustard Compounds; Rituximab | 2012 |
Retreatment with bendamustine-containing regimens in patients with relapsed/refractory chronic lymphocytic leukemia and indolent B-cell lymphomas achieves high response rates and some long lasting remissions.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, B-Cell; Male; Middle Aged; Neoplasm Staging; Nitrogen Mustard Compounds; Recurrence; Remission Induction; Retreatment; Treatment Outcome | 2013 |
Letter from the editor.
Topics: Antineoplastic Agents, Alkylating; Bendamustine Hydrochloride; Congresses as Topic; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma; Nitrogen Mustard Compounds | 2012 |
Bendamustine-induced "flagellate dermatitis".
Topics: Antineoplastic Agents, Alkylating; Bendamustine Hydrochloride; Drug Eruptions; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Nitrogen Mustard Compounds | 2012 |
Bendamustine in the treatment of hematologic malignancies. Introduction.
Topics: Antineoplastic Agents; Bendamustine Hydrochloride; Hematologic Neoplasms; Hodgkin Disease; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Non-Hodgkin; Multiple Myeloma; Nitrogen Mustard Compounds | 2002 |
In vitro studies with bendamustine: enhanced activity in combination with rituximab.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antigens, CD20; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Bendamustine Hydrochloride; Carcinoma; Complement System Proteins; Drug Synergism; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Non-Hodgkin; Nitrogen Mustard Compounds; Rituximab; Tumor Cells, Cultured | 2002 |
Bendamustine in the treatment of chronic lymphocytic leukemia: results and future perspectives.
Topics: Aged; Aged, 80 and over; Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antibodies, Neoplasm; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; B-Lymphocytes; Bendamustine Hydrochloride; Cladribine; Drug Administration Schedule; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Neoplasm Recurrence, Local; Nitrogen Mustard Compounds; Remission Induction; Rituximab; Salvage Therapy; Vidarabine | 2002 |
In vitro evaluation of bendamustine induced apoptosis in B-chronic lymphocytic leukemia.
Topics: Antineoplastic Agents; Apoptosis; bcl-2-Associated X Protein; Bendamustine Hydrochloride; Blotting, Western; Flow Cytometry; In Vitro Techniques; Leukemia, Lymphocytic, Chronic, B-Cell; Monocytes; Nitrogen Mustard Compounds; Poly(ADP-ribose) Polymerases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-2 | 2002 |
Bendamustine in relapsed or refractory chronic lymphocytic leukemia.
Topics: Bendamustine Hydrochloride; Dose-Response Relationship, Drug; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Nitrogen Mustard Compounds; Secondary Prevention | 2005 |
Recurrent chemotherapy-induced tumor lysis syndrome (TLS) with renal failure in a patient with chronic lymphocytic leukemia - successful treatment and prevention of TLS with low-dose rasburicase.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Creatinine; Cyclophosphamide; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Nitrogen Mustard Compounds; Recombinant Proteins; Renal Insufficiency; Tumor Lysis Syndrome; Urate Oxidase; Uric Acid; Vidarabine | 2005 |
Remission of a B cell CLL-associated membranoproliferative glomerulonephritis Type I with rituximab and bendamustine.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Bendamustine Hydrochloride; Drug Therapy, Combination; Glomerulonephritis, Membranoproliferative; Humans; Immunologic Factors; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Nephrotic Syndrome; Nitrogen Mustard Compounds; Remission Induction; Rituximab | 2008 |
Treanda approved for chronic lymphocytic leukemia.
Topics: Antineoplastic Agents; Bendamustine Hydrochloride; Drug Approval; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Nitrogen Mustard Compounds; United States; United States Food and Drug Administration | 2008 |
Effective treatment with rituximab in a patient with refractory prolymphocytoid transformed B-chronic lymphocytic leukemia and Evans syndrome.
Topics: Aged; Anemia, Hemolytic, Autoimmune; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Bone Marrow; Humans; Immunophenotyping; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Nitrogen Mustard Compounds; Remission Induction; Rituximab; Treatment Failure | 2001 |
In vitro induction of apoptosis of neoplastic cells in low-grade non-Hodgkin's lymphomas using combinations of established cytotoxic drugs with bendamustine.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Bendamustine Hydrochloride; Drug Interactions; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Non-Hodgkin; Nitrogen Mustard Compounds; Tumor Cells, Cultured | 2001 |
Anti-CD20 antibody (IDEC-C2B8, rituximab) enhances efficacy of cytotoxic drugs on neoplastic lymphocytes in vitro: role of cytokines, complement, and caspases.
Topics: Amino Acid Chloromethyl Ketones; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antigens, CD20; Antigens, Neoplasm; Antineoplastic Agents; Apoptosis; Bendamustine Hydrochloride; Burkitt Lymphoma; Caspase 7; Caspase 8; Caspase 9; Caspase Inhibitors; Caspases; Cladribine; Complement Activation; Complement System Proteins; Cysteine Proteinase Inhibitors; Doxorubicin; Drug Synergism; Gene Expression Regulation, Leukemic; Gene Expression Regulation, Neoplastic; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Interleukins; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, B-Cell; Lymphoma, Follicular; Mitoxantrone; Neoplasm Proteins; Nitrogen Mustard Compounds; Oligopeptides; Rabbits; Rituximab; Tumor Cells, Cultured; Tumor Necrosis Factor-alpha | 2002 |